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Background 
Rheumatoid arthritis (RA) and Crohn’s disease (CD) are two among a group of immune-
mediated inflammatory diseases (IMIDs). These diseases are common, collectively affecting as 
many as two million Americans and as many as 28 million people worldwide. They have 
different clinical presentations but may have a common pathogenesis. An over-expression of 
tumor necrosis factor (TNF) and interleukin-6 (IL-6) have been proffered as a causal factor for 
IMIDs. These and other IMIDs may co-occur in patients, and it has been shown that patients 
with one IMID may have an increased risk of another IMID. What is not clear is whether the co-
occurrence of a second IMID is caused by the existence of the first IMID. 
 iv 
Mendelian Randomization (MR) has emerged as an important tool that facilitates causal 
inference from observational studies. This study design can allow for avoidance of a common 
problem in epidemiologic studies, confounding, because it takes advantage of the random 
allocation of genetic make-up at conception. MR compares disease status by genetically 
predicted exposure to obtain unconfounded estimates. MR implementation has been facilitated 
by the increasing availability of Genome-wide association studies (GWAS) genotyping millions 
of single nucleotide polymorphisms (SNPs).  
A recent extension of Mendelian Randomization is to conduct Phenome-wide Association 
Studies (PheWAS) to use genetic variants that predict response to treatment, for drug target 
validation and repurposing studies using these genetic variants as genetic proxies to identify both 
on-target and off-target mechanistic effects of a pharmacologic intervention. As an example, the 
minor allele of rs7529229, which is on the IL6R gene and is associated with interleukin 6 (IL6) 
concentrations, predicts response to tocilizumab, a pharmacologic treatment approved for the 
treatment of RA. A further goal of the current study is to use PheWAS to explore the scope for 
re-purposing tocilizumab as to characterize the off-target effects of this treatment.  
The hypothesis that one IMID causes another was addressed by two MR studies, in which one of 
the IMIDs was tested as a cause of the other. Additionally, a PheWAS evaluated whether genetic 
proxies of therapeutic treatments for RA can identify any new effects. 
Methods 
A two-sample Mendelian randomization study was conducted to assess the possible causal effect 
of RA on CD for the first specific aim. The primary analysis used the inverse variance weighted 
(IVW) method; sensitivity analyses include weighted median, MR-Egger, and MR-PRESSO 
 v 
(Pleiotropy RESidual Sum and Outlier) methods. Genetic predictors of RA obtained from a 
GWAS including 22 studies with participants from European and Asian backgrounds, with 
19,234 cases and 61,565 controls, were applied to summary genetic associations for CD, from 
the International IBD Genetics Consortium (IIBDGC), (17,897 cases, 33,977 controls) of 
European descent.  
A two-sample Mendelian randomization study was conducted to assess a possible causal role of 
CD on RA for the second specific aim. The primary analysis used IVW to determine the effect of 
CD on RA. Sensitivity analyses included weighted median, MR-Egger, and MR-PRESSO. 
Genetic predictors of CD from summary statistics from the IIBDGC, (17,897 cases, 33,977 
controls of European descent) were applied to a GWAS of RA that included 22 studies including 
patients of European and Asian backgrounds (19,234 cases, 61,565 controls).  
One single nucleotide polymorphism (SNP) predicting response to TCZ in RA patients was 
identified, rs7529229. For the third specific aim, the PheWAS (Phenome-wide Association 
Study) function in the MR-base web-based application was used to identify traits associated with 
this SNP to use as potential drug targets for inclusion in the analysis. As this is an agnostic 
search, a p-value threshold of 2.4x10-6  was used based on a Bonferroni correction. The PheWAS 
provided effect estimates (provided as beta) and p-values which enabled evaluation of potential 
new targets for TCZ.  
Results 
For specific aim 1, all four analyses showed a protective effect of RA on CD. (IVW odds ratio 
[OR] 0.89, 95% confidence interval [CI] 0.77-1.00, p=0.042; MR-Egger OR 0.71, 95% CI 0.50-
 vi 
0.93, p=0.004; weighted median OR 0.78, 95% CI 0.72-0.84, p=8.4x10-15; MR-PRESSO OR 
0.92, 95% CI 0.84-1.00, p= 0.047).  
For specific aim 2, the primary analysis and all three sensitivity analyses showed no causal effect 
of CD on RA (IVW OR 0.97, 95% CI 0.88-1.07, p=0.59; weighted median OR 0.98, 95% CI 
0.94-1.03, p=0.49; MR-Egger OR 0.92, 95% CI 0.67-1.18, p=0.54, MR-PRESSO OR 1.00, 95% 
CI 0.64-1.36, p=0.90). 
For specific aim 3, the SNP rs7529229 predicting response to TCZ in RA was associated with 
21,031 traits. Seventeen of these met the Bonferroni corrected p-value threshold for statistical 
significance. Of these, three were excluded from consideration: abdominal aortic aneurysm, due 
to missing beta, and two traits described as “Blood clot  DVT  bronchitis  emphysema  asthma  
rhinitis  eczema  allergy diagnosed by doctor: None of the above,” as these did not indicate a 
trait. Among the other 10 unique traits, four showed an inverse association with the SNP 
predicting response to TCZ: RA, coronary heart disease (CHD), and two blood counts (red cell 
distribution width and granulocyte percentage of myeloid white cells). Six traits were positively 
associated with this SNP, meaning use of TCZ may increase the risk of the following: eczema, 
asthma, a less specific trait of hay fever, allergic rhinitis or eczema, tonsillectomy, and two 
additional blood counts (mean corpuscular hemoglobin and monocyte percentage of white cells). 
Discussion  
The first MR study suggests that RA protects from the development of CD. It is possible this is 
due to issues with the data sources, or the infrequency of co-occurrence of the two diseases. 
There also may be a currently unknown biological mechanism causing this effect. 
 vii 
The second MR study suggests that CD does not cause rheumatoid arthritis. Co-occurrence of 
CD and RA is fairly uncommon, and when it does occur, may be due to shared causes of both 
conditions such as overexpression of TNF-a or IL-6.  
The PheWAS did not yield any new targets for tociluzumab. As rs7529229 predicts response to 
TCZ in RA patients, it was expected that there would be an inverse association between the SNP 
and RA. Other studies have already evaluated the inverse association of this SNP with CHD, 
suggesting CHD as a potential target for TCZ. The positive association with asthma was 
somewhat unexpected, as some studies have suggested a potential for IL-6 inhibition in asthma. 
The positive association with eczema were expected as this was reported in the clinical trial 
program for TCZ and in other PheWAS of SNPs associated with IL-6 levels. The impact of TCZ 
on various blood counts is difficult to interpret.  The direction of the association with asthma is 
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Chapter 1: An Assessment of Potential Causal Pathways Between  Two Autoimmune 
Diseases: Mendelian Randomization Studies of Rheumatoid Arthritis and Crohn’s Disease; 
and A Phenome-Wide Association Study to Assess Potential New Targets for Tocilizumab, 
an Interleukin-6 Inhibitor  
 
SPECIFIC AIMS 
Rheumatoid arthritis (RA) and Crohn’s disease (CD) are two among a group of immune-
mediated inflammatory diseases (IMIDs). These diseases are common, collectively affecting as 
many as two million Americans [1-4]  and as many as 28 million people worldwide. [5-7] They 
have different clinical presentations but may have a common pathogenesis. An over-expression 
of tumor necrosis factor (TNF) has been proffered as a causal factor for IMIDs. These and other 
IMIDs may co-occur in patients, and it has been shown that patients with one IMID may have an 
increased risk of another IMID. What is not clear is whether the co-occurrence of a second IMID 
is caused by the existence of the first IMID. [8-10] 
Mendelian Randomization (MR) has emerged as an important tool that facilitates causal 
inference from observational studies. This study design can allow for avoidance of a common 
problem in epidemiologic studies, i.e., confounding,  [11] because it takes advantage of the 
random allocation of genetic make-up at conception. MR compares disease status by genetically 
predicted exposure to obtain unconfounded estimates. MR implementation has been facilitated 
by the increasing availability of genome-wide association studies (GWAS) genotyping millions 
of single nucleotide polymorphisms (SNPs).  
A recent extension of Mendelian Randomization is to conduct Phenome-wide Association 
Studies (PheWAS) to use genetic variants that predict response to treatment, [12] for drug target 
validation and repurposing studies using these genetic variants as genetic proxies to identify both 
on-target and off-target mechanistic effects of a pharmacologic intervention. As an example, the 
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minor allele of rs7529229, which is on the IL6R gene and is associated with interleukin 6 (IL6) 
concentrations, predicts response to tocilizumab, a pharmacologic treatment approved for the 
treatment of RA. [13] A further goal of the current study is to use PheWAS to explore the scope 
for re-purposing tocilizumab as to characterize the off-target effects of this treatment. 
The hypothesis that one IMID causes another was addressed by two MR studies, in which one of 
the IMIDs was tested as a cause of the other. Additionally, a PheWAS evaluated whether genetic 
proxies of therapeutic treatments for RA can identify any new effects. The three specific aims of 
the proposed study are listed below. 
Specific aim 1: Does RA cause Crohn's disease?  
Specific aim 2: Does Crohn’s disease cause RA? 
Specific aim 3: Can drug target validation/repurposing predict additional effects of an existing 












BACKGROUND AND SIGNIFICANCE 
RA and CD are important among the autoimmune diseases due to high prevalence and resulting  
high number of disability-adjusted life years (DALYs), a measure of early mortality and ill 
health. [14]. Autoimmune diseases tend to be more common among women than men, for 
reasons that are not well understood. One estimate suggests that while about 8% of the 
population lives with an autoimmune disease, 78% of those are women. A hypothesis offered for 
a female preponderance suggests that since women have an increased antibody response to 
infection, vaccination and trauma compared to men, these antibodies, which protect against 
infection, also cause immune disease risk. [15] 
Many treatments are approved for the treatment of RA and CD. MR studies focused on drug 
target validation and repurposing use genetic differences as proxies to identify both on-target and 
off-target mechanistic effects of a pharmacologic intervention. [13] Characterizing the effects of 
such genetic proxies of treatments may identify additional disease targets of existing treatments 
as well as off-target effects.  
Incidence/prevalence/mortality 
RA 
Rheumatoid Arthritis (RA) is a common autoimmune disease characterized by pain and 
inflammation in the joints, leading to joint damage and significant loss of function. [16] Age of 
onset of RA is typically between the age of 30 and 60 years. Estimates of the median age at 
disease onset range from 45-58 years. [17, 18] About 1.5 million Americans live with RA; [19] 
worldwide, RA may affect as many as 21 million people. [5, 7] 
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RA is common in the U.S. and globally. Reports of incidence vary depending on method of 
ascertainment. For example, a population-based cohort of adults age 18 and older in Olmstead 
County, Minnesota, reported age- and sex-adjusted RA incidence of 40.9 per 100,000 population 
(53.1 per 100,000 population in women, 27.7 per 100,000 population in men). Diagnostic criteria 
included the 1987 American College of Rheumatology criteria, verified via participants’ medical 
records. [19] A retrospective cohort study using a US medical claims database (PharMetrics) 
reported cumulative incidence of RA in adults 18 years and older in 2006 of 73 per 100,000 
population (95% confidence interval (CI) 70–75 per 100,000 population). Cumulative incidence 
was 100 per 100,000 in women and 44 per 100,000 in men. Claims data may reflect an under-
estimate compared to population-based estimates as not all RA patients may require health care 
contacts meeting the criteria for inclusion in a claims cohort. [20] 
Prevalence is higher in developed nations compared to developing nations. The Global Burden of 
Disease 2010 study estimated global prevalence of RA from age 5 to 100 to be 0.24% (95% CI 
0.23% to 0.25%), 0.34% in North American men, and 0.63% in North American women. [21] In 
the  Olmstead County, Minnesota cohort, prevalence of RA was 0.72% which, when applied to 
the US population (2005), suggests that about 1.5 million adults live with RA. [19] In the 
National Health and Nutrition Examination Survey (NHANES), a population-based study, the 
age-adjusted prevalence of RA was 3.8% in 2014. [1] This disparity may reflect the difference 
between self-report (as in NHANES) and health care provider diagnosed disease (as in the 
Olmstead and GBD studies).  
Based on 84 unique cohorts published from 1953-2008, overall, RA patients had an increased 
risk of death compared to people without RA, with standardized mortality ratios (SMRs) 
generally between 1.2 and 1.3 in inception cohorts. Causes of death are similar in RA patients 
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and non-RA patients. Cardiovascular disease is the most common cause of death among RA 
patients, at an earlier age than among non-RA patients. Infections, gastrointestinal diseases, and 
pulmonary disease are more common causes of death in RA patients. Interestingly, cancer deaths 
are overall decreased compared to the general population, with the exception of lymphoma, 
which may be increased among persons treated with biologics and disease-modifying 
antirheumatic drugs (DMARDs). [22] 
CD 
Crohn’s disease (CD) is an autoimmune disease characterized by abdominal pain, diarrhea, and 
fatigue, weight loss, fever, growth failure, anemia, and/or recurrent fistulas. [23] There are two 
peak age ranges for onset of CD. The first is from 15-29 years and the second is from 55-59 
years. [24] In the U.S., between 593,000 to 780,000 people live with CD, with an estimated 
33,000 new patients diagnosed each year, [4] and worldwide, as many as 7 million people live 
with CD. [6] 
The estimated incidence of CD in a US cohort was 10.7 per 100,000 person-years (95% 
confidence interval [CI] 9.1-12.3 per 100,000 person-years). [3, 4] Other estimates of incidence 
in North America range from 6.3 per 100,000 person-years in the US to 23.82 per 100,000 
person-years in Canada. There is variability by country in Europe, with ranges from 0.0 per 
100,000 person-years in Greenland to 15.4 per 100,000 person-years in Italy. [25]  
Prevalence is higher in developed nations compared to developing nations. Prevalence estimates 
range from 0.0963% in the US to 0.318.5% in Canada. Prevalence estimates in Europe vary 
widely, from 0.015% in Romania to 0.322% in Germany. [25]  
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Mortality risk from intestinal cancer is generally similar in CD patients compared to the general 
population, although one study reported a slightly increased risk among CD patients with 
extensive small bowel disease and among those who were aged 20–29 years at diagnosis. [26]  
All-cause mortality is higher in CD than in the general population; standardized mortality ratio 
(SMR) of 1.45 (95% CI 1.34-1.58) has been reported, and mortality from digestive conditions, 
all cancers, digestive cancers, colorectal cancer, lymphatic and lung cancers were significantly 
higher compared to the general population. [27] The Olmstead County (Minnesota) cohort study 
also reported a higher risk of mortality among CD patients (SMR, 1.25; 95% CI, 0.98-1.57). 
Specifically, in this cohort, 9% of deaths were attributed to CD complications, including 
intestinal fistula, perforation, or abscess. [28] 
Drug target validation/repurposing 
Genetic validation of potential drug treatments is increasingly used to facilitate drug 
development and anticipate side-effects. Mutations in the PCSK9 gene have been found to 
predict familial hypercholesterolemia and coronary artery disease; leading to two drugs that 
target this gene: evolocumab (Repatha, marketed by Amgen) and alirocumab (Praluent, marketed 
by Regeneron). [29] Lovostatin, the first of the statins and approved for primary and secondary 
prevention of coronary artery disease, inhibits HMG-CoA reductase. Many other genetic 
differences that identify susceptibility to disease have been discovered using GWAS, creating 
many potential drug targets. [30] Interleukin 6 is implicated as a cause of RA, and tocilizumab 
(Actemra, marketed by Genentech) is a therapy targeting IL-6 inhibition. [13] Tumor necrosis 
factor alpha (TNF-a) is implicated in CD and RA; adalimumab (Humira, marketed by AbbVie) 
targets TNF-a. [31] Schmidt and colleagues describe four genes (HMGCR, PCSK9, NPC1L1, 
and CETP) with effects on lipids that have variants with specific drug targets that are approved 
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or are in clinical trials for coronary heart disease (CHD). Notably, the drugs with genetic 
validation as modulating both lipids and CHD were successful in clinical trials, but those that 
failed genetic validation for CHD (drugs targeting CETP) were not. The authors also provide 
guidance on the “selection of genes encoding druggable proteins” for use in drug target 
validation MR studies. [32] Nelson and colleagues used the Informa Pharmaprojects database to 
identify 22,270 drugs with 1,824 genetic targets, creating 19,085 drug-target pairs covering 705 
indications, including RA and CD. Many drug-target pairs have been identified for RA and CD 
(651 for RA; 134 for CD). [33]  
Notably, genetic variants that have been identified as predictors of treatment response for RA 
(and other diseases) may have mechanistic effects on other outcomes. Research has been done on 
tocilizumab and adalimumab to look for additional effects; for example, the Interleukin-6 
Receptor Mendelian Randomisation, Consortium has shown a protective effect on coronary heart 
disease of the minor allele of rs7529229 allele, a proxy for tocilizumab use [13] and neurological 
outcomes have been identified as effects of the rs10210302 variant, a proxy of adalimumab. [34] 
However, whether tocilizumab, an IL-6 inhibitor, has effects on other diseases in which IL-6 is 
involved is unclear but important. 
Public Health Impact  
People with RA are at risk for falls and other injuries and may be unable to work. [35] One 
estimate of health care costs in the U.S. attributable to RA in 2013 was $140 billion. [36] The 
National Health Interview Survey (NHIS) reported that 43.5% of individuals with RA had 
limitations to activity related to their RA. [37] In the Global Burden of Disease 2010 study, RA 
was ranked as the 42nd highest contributor to global disability, and years lived with disability 
(YLDs) were 55 per 100,000 population (in 2010), and higher in females than in males (87.84 
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per 100,000 versus 22.46 per 100,000). [21]; the Global Burden of Disease 2017 study reported 
YLDs at 2,620,000. [14]  
The Global Burden of Disease study reported YLDs at 335,400 for CD. [14] In a review of 
Health-Related Quality of Life (HQOL) studies, compared to healthy controls, CD patients 
scored worse on physical, social, and emotional function. Compared to patients with ulcerative 
colitis, patients with CD scored similar to or worse on general HQOL measures. [38] Estimated 
direct costs of CD in in the U.S. in1998 (including inpatient and outpatient visits and pharmacy) 
were $708 million; indirect costs were estimated at $75 million and included costs associated lost 
productivity. [39] 
The cost of developing new molecular entities (NMEs) is in the billions of dollars, and can take, 
on average, over 12 years. [29, 30] Less than 10% of drugs are eventually approved by the US 
Food and Drug Administration (FDA) or another health authority. [29]  Drug targets with genetic 
associations with disease have a much higher likelihood of succeeding and receiving regulatory 
approval. [29, 33, 40] More specifically, if causal genetic variants can be identified through 
genome-wide association studies (GWAS), this genetic evidence has been shown to increase 
drug approval more than two-fold. [29] Using genetic evidence could decrease cost of drug 
development, due to fewer failed clinical trials. One estimate suggests that if the proportion of 
drugs in development with genetic targets were increased from 15% (the current proportion) to 
50%, research and development costs would decrease by anywhere from 9% to 35%. [29]  
Summary of MR research of RA and CD causes, and PheWAS research on drug targets 
Rheumatoid arthritis and CD are prevalent and debilitating diseases of great public health 
importance. Causes of these diseases are not well understood. An over-expression of tumor 
necrosis factor (TNF) has been proffered as one causal factor for IMIDs [10] but there are likely 
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other causes as well, given their multifactorial nature.  A number of MR studies have evaluated 
various potential causes of RA while fewer have looked at CD.  
RA 
Li and colleagues conducted a meta-analysis of MR studies to assess the role of interleukin-6 in 
RA; they determined that reduced IL-6 may be causally linked to increased risk of RA overall 
and especially in the Asian population. [41] The Interleukin 1 Genetics Consortium also 
evaluated the causal effect of genetic inhibition of IL-6 on RA and type 2 diabetes, coronary 
heart disease, ischemic stroke, and abdominal aortic aneurysm (n=453,411). Results suggested 
causal associations of IL-6 inhibition with RA (reduced risk) as well as cardiovascular disease 
(increased risk). [42] Vitamin D has also been considered as a risk factor for RA, with variable 
results. One MR study reported vitamin D-associated SNPs were not associated with RA. [43] 
Yarwood and colleagues evaluated 6 SNPs associated with vitamin D to determine response to 
anti-TNF-alpha inhibitor therapy in RA patients; one SNP showed a poorer response to TNF-
alpha inhibitor therapy. [44] However, observational studies in patients can be difficult to 
interpret, because they are open to selection bias. An MR study reported that linoleic acid was 
inversely associated with RA (i.e., protective) (OR 0.97, 95% CI 0.95-0.98). [45] 
CD 
A literature search yielded only abstracts, describing MR studies of CD; no full published papers 
were found. Three abstracts, all by Parisinos and colleagues, describe the role of interleukein-6 
in the pathogenesis of CD. [46-48] Two additional abstracts by Porcu and colleagues describe 
pleiotropic effects of the GSDMB gene on diseases that are “suggestive of mechanistic 
connections” including RA and CD. [49, 50]   
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Drug target validation/repurposing 
Studies have identified SNPs associated with soluble fraction of the IL6 receptor (sIL6R) and 
reviewed associated traits. PheWAS have then evaluated traits associated with such SNPs across 
the phenome. For example, rs4129267, which is an sIL6R variant, was found to have positive, 
statistically significant associations with monocyte count, mean platelet volume, eczema, and 
asthma. Mendelian randomization using 34 SNPs associated with sIL6R circulating levels 
showed causal inverse associations with various types of stroke, atrial fibrillation, coronary 
artery disease, abdominal aortic aneurism, and RA, suggesting protective effects of IL-6 
inhibition, and positive associations with eczema and asthma, suggesting IL-6 inhibition 
increases risk of these diseases. Also included in these analyses were heritable longevity; sIL6R 
was positively associated with parental age at death, and various blood parameters, of which only 
C-reactive protein was significantly, inversely associated with sIL6R levels. [51] Another 
PheWAS reviewed other IL6R SNPs (rs2228145; rs4129267), in patients in the Million Veteran 
Program (MVP) with results replicated in data from the UK Biobank and Vanderbilt University 
Biobank. Significant inverse associations between these SNPs and the following traits were 
found: aortic aneurysm, ischemic heart disease (including coronary atherosclerosis, ischemic 
heart disease, and myocardial infarction), and vascular diseases such as peripheral vascular 
disease and atherosclerosis of the extremities. Significant positive associations were identified 
for skin conditions such as atopic dermatitis (eczema), seborrheic dermatitis, and 
erythematosquamous dermatosis. Several pulmonary, renal, and eye conditions were also 
positively associated with these IL6R SNPs, as were two musculoskeletal conditions (acquired 
deformities of finger and gouty arthropathy). [52] While these two PheWAS identified traits 
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associated with SNPs that are IL-6 inhibitors, a search of the literature did not find any PheWAS 
that specifically evaluated traits associated with the specific SNP rs7529229. 
Innovation 
This study will fill an important gap in the literature by evaluating the causal associations 
between two IMIDs. It is important to determine whether a second IMID is caused by having a 
first IMID. RA and CD all have a substantial public health impact, causing significant pain, lost 
time and productivity at work and physical limitations. These are chronic illnesses patients may 
live with for decades and any one of them may be debilitating, leading to significant pain, lost 
productivity, and health care costs; a second IMID will significantly compound these problems. 
Long-term, this information will be helpful for health care providers who care for patients with 
one diagnosed IMID; it can encourage close surveillance with regard to subsequent development 
of another IMID, if appropriate. This information may be helpful in the pharmaceutical sector, 
where already treatments being developed for one IMID are tested and health authority approvals 
are received for the treatment of other IMIDs, though posology may be different (e.g., tofacitinib 
[Xeljanz, Pfizer],which is approved for three IMIDs: RA, ulcerative colitis, psoriatic arthritis; 
etanercept [Enbrel, Pfizer/Amgen], approved for five IMIDs: RA, plaque psoriasis, psoriatic 
arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; adalimumab, 
which is approved for 10 IMIDs, including both RA and CD [Humira, AbbVie]). [31, 53, 54] 
Drug target repurposing can identify novel disease areas for existing therapies to bring new 
treatment options to patients while cutting down on time and cost in clinical trials. [29, 30, 33] 
These studies address the study questions using novel design. MR is an epidemiologic study 
design that has some similarities with randomized controlled trials and avoids confounding. MR 
takes advantage of the natural randomization of genetic material at conception. MR’s ability to 
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provide unconfounded estimates is important.[55] Other designs with similar properties exist, 
such as sibling or twin studies, but are not always feasible, whereas the investment in genetic 
studies has provided resources for MR. PheWAS examine the associations of specific genotypes 
with all phenotypes, providing an important tool in the search for new drug targets for existing 
therapies. The growth of the field of genetics and the ongoing publication of new GWAS is 
enabling the expansion of the use of MR and PheWAS to answer more questions using these 
methods. Mendelian Randomization and PheWAS are now also relatively easy to implement 
using an online tool, MR-Base, along with available R code. [56, 57]  
STATISTICAL APPROACH  
Conceptual/Theoretical Framework  
Mendel’s law of independent assortment states inheritance of traits is independent of inheritance 
of other traits.  Davey Smith and Ebrahim described Mendelian randomization as taking 
advantage of “the random assortment of alleles at the time of gamete formation”  [58, 59] to 
obtain unconfounded proxies of exposure. Genetic variants are independent of typical behavioral 
and environmental confounders; for this reason, Mendelian randomization is similar to a 
randomized study design in avoiding confounding but remains open to selection bias, because 
the randomization takes place before rather than after recruitment.  
MR is an instrumental variable analysis with genetic variants as the instrument variable (IV). An 
instrumental variable is used to measure the effect of an exposure on an outcome when the 
exposure is open to confounding. An instrumental variable is typically described as needing to 
meet three conditions: relevance, exclusion-restriction and independence. Relevance indicates 
that the instrument is associated with the exposure. Exclusion-restriction indicates that the 
instrument affects the outcome only via effects on the exposure. Independence indicates that the 
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instrument does not share common causes with the outcome.  [60-62]  These assumptions are 
applied as follows in an MR study: the genotype (as the IV) must be associated with the 
phenotype/exposure disease (relevance), the genotype affects the outcome disease only through 
the phenotype (exclusion-restriction), and there are no common causes (confounders) of the 
association between genotype and the outcome disease of interest. Estimates for an MR study are 
obtained by combining the Wald estimates (genetic variant on outcome divided by genetic 
variant on exposure). 
The Directed Analytic Graph (DAG) in Figure 1.1 describes MR as an instrumental variable. 
The assumptions are indicated by the arrow from the IV to exposure (relevance), the lack of 
arrows from instrument to outcome (exclusion-restriction), and the lack of arrows from 
confounder to instrument (independence). 
Preliminary data  
A review of the literature provided background data on RA, CD, and drug target validation. The 
literature also provided background, on available MR studies on the two diseases and the use of 
drug target validation, as described above. The literature also yielded data on available GWAS 
that may be appropriate for use in the analysis (see below). However, no data were found 
describing the possible causal associations between the two IMIDs under study.   
Study design  
For the first two specific aims, a two sample MR study was implemented using a GWAS that 
provides genetic associations with the exposure and another GWAS that provides genetic 
associations with the outcome, because this approach enables research questions to be answered 
even if one study including both exposure and outcome does not exist. [63] Estimates of the 
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effect of exposure on outcome can then be made using a well-established technique, separate 
sample instrumental variable analysis, which only requires summary statistics from the GWAS, 
which are available in MR-base. [57]  
For the third specific aim, the Phenome-Wide Association Study (PheWAS) function in the MR-
base web-based application [64] was used to identify traits associated with this SNP to use as 
potential drug targets for tocilizumab.  
Study population and eligibility criteria  
The study populations were those included in published, publicly available, curated GWAS 
available in MR-base, [57] giving genetic associations with disease onset. Typically, to date most 
large GWAS have largely been conducted in middle-aged and older people of European descent. 
For the first two specific aims, the exposure was the disease of interest (RA or CD); the 
outcomes included the other autoimmune disease of interest.  The third specific aim used the 
SNP rs7529229, which predicts response to tocilizumab in RA, as the exposure. 
Data sources, collection, and management  
MR-base [57] is a web-based platform that contains a curated catalog of summary statistics from 
many GWAS covering many diseases. Using the search function in this utility, it is possible to 
select instruments for an exposure and assess its effects on the disease areas of interest using 
summary statistics. The data are aggregated, deidentified, and publicly available. 
The specific GWAS chosen for the three specific aims are described below.  
RA: Specific aim 1 (exposure); Specific aim 2 (outcome) 
A large, curated GWAS of RA which includes 22 combined GWAS (18 studies including 
participants of European background, 4 studies including those of Asian background). The 
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original data sources contained RA cases, of which 88.1% were seropositive for anti-citrullinated 
peptide antibody (ACPA), 9.3% were seronegative, and 2.6% had unknown antibody status. All 
RA cases had confirmed diagnosis according to the 1987 American College of Rheumatology 
criteria [65] or were diagnosed by a rheumatologist. The sample includes 19234 cases and 61565 
controls. Geographically matched controls were drawn from multiple sources, including an age-
related macular degeneration GWAS, a myocardial infarction GWAS, the UK 1958 birth cohort, 
the UK National Blood Services cohort, and non-autoimmune disease cases from the Wellcome 
Trust Case Control Consortium (WTCCC). [66, 67] 
CD: Specific aim 1 (outcome); Specific aim 2 (exposure) 
A large, curated GWAS of Crohn’s disease is the International IBD Genetics Consortium 
(IIBDGC), which combined data from six CD GWAS, all of European descent, and identified a 
total of 71 loci including 17897 cases and 33977 controls. Patients in the IIBDGC-consortium 
GWAS were enrolled in medical centers in the U.S. and Canada (Cedars-Sinai Medical Center; 
Johns Hopkins University; University of Chicago; University of Montreal; University of 
Pittsburgh; University of Toronto Genetics Research Centers); CD was physician diagnosed 
using x-rays, endoscopy reports, pathology reports, and other diagnostic tools. The GWAS 
included geographically matched controls as well as additional age- and ethnicity-match controls 
from the New York Health Project. [67-71]  
rs7529229, predictor of response to tocilizumab: Specific aim 3 (exposure) 
Forty studies from the US, UK, and Europe contributed to the identification of the IL-6R SNP 
rs7529229 as associated with increased circulating IL-6 concentration, consistent with IL-6 
inhibition from TCZ infusions for RA every four weeks (posology 4-8mg/kg). Total participants 
in these studies was 133,44. Mean age of participants of contributing studies ranged from late 
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40s to mid 70s, with one outlier (mean age 25.6), and with one study not reporting mean age. 
[13] 
Sampling/Recruitment procedures  
This study is a secondary analysis of publicly available data. The sampling/recruitment 
procedures for the underlying studies were reported, where available, and their implications for 
validity of the estimates considered. 
Primary and secondary outcome definitions  
RA: All RA cases in the combined GWAS described above had a clinical diagnosis of RA by a 
rheumatologist, and/or met the 1987 American College of Rheumatology diagnostic criteria. [65, 
66] 
CD: All CD cases in the IIBDGC-consortium GWAS were diagnosed by physicians using x-
rays, endoscopy reports, pathology reports, or other diagnostic tools. [67-71] 
Data analysis plan  
Two-sample MR analyses were conducted for all three specific aims. For the first two specific 
aims, the primary analysis used the inverse variance weighted (IVW) method; sensitivity 
analyses were weighted median, MR-Egger, and MR-PRESSO  (Pleiotropy RESidual Sum and 
Outlier) methods, which essentially compare the estimates from different ways of combining the 
genetic variant specific Wald estimates. Publicly available summary statistics from GWAS 
included in MR-base were used; the GWAS for each exposure and outcome is described above 
in the data sources section.  
The analyses for the first two specific aims was conducted in the MR-base web application, [57] 
except for the MR-PRESSO sensitivity analyses, which was conducted in R. [56] A two sample 
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MR in MR-base is implemented in several steps. The first step is to select exposures from among 
GWAS available in the data catalog. The second step is to choose outcomes, from among those 
available in the catalog. Next, in the web-based application, the “Run MR” selection provides the 
inverse variance weighted, weighted median, and MR-Egger analyses. This utility matches allele 
direction for the SNPs across data sources, replaces palindromic SNPs as necessary and finds 
proxies for SNPs predicting the exposure but unavailable for the outcome. MR-PRESSO was 
conducted separately in R. [56, 72, 73] 
Wald estimates show the effect of the exposure on the outcome for each included SNP. [74] For 
the first two specific aims, these Wald estimates were combined in a meta-analysis of the effect 
of the exposure on the outcome for each included SNP (ratio of SNP on outcome to SNP on 
exposure); this is the inverse variance weighted method and is the primary analysis for the first 
two specific aims. [74] This method uses the first-term of Fieller’s theorem (variance of SNP on 
outcome divided by SNP on exposure) [75] to approximate the SNP-specific variance. This 
method assumes each included instrument fulfills the assumptions of an IV. Inclusion of 
pleiotropic SNPs may decrease the validity of this method. 
The additional methods were used as sensitivity analyses to determine whether IV assumptions 
are violated or if an outlier SNP is driving an effect estimate. These sensitivity analyses use 
different assumptions. Two that were run in the MR-base platform include weighted median and 
MR-Egger. A weighted median of the SNP-specific Wald estimates is valid as long as >50% of 
the weight is contributed by valid instruments. [76] MR-Egger relaxes the assumption that there 
are no pleiotropic effects; this method is robust to invalid instruments, but assumes there no 
genetic confounders, i.e., the genetic instruments do cause a confounder of exposure and 
outcome. This is usually termed the Instrument strength independent of direct effects (InSIDE) 
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assumption. [77] MR-PRESSO identifies and removes outliers due to horizontal pleiotropy and 
tests differences in the estimates before and after this correction. MR-PRESSO requires that 
>50% are valid instruments. Removing outliers in this way leads to an unbiased estimate, [72, 
73] but all these methods assume the InSIDE assumption. 
When selecting the GWAS representing the disease area, SNPs with p-values below 5x10-8 were 
extracted and used in the MR analysis, to ensure that the SNPs strongly predicted the exposure, 
i.e., at genome wide significance, rather than being chance associations. Different SNPs are often 
very close together on the human genome, so their associations with a phenotype can be highly 
correlated. The r2 (correlation coefficient) threshold for identifying correlations between SNPs 
(linkage disequilibrium) was 0.001, only keeping SNPs with correlation below this threshold 
gives independence between genetic variants predicting the exposure.[78, 79] 
The F-statistic was calculated for each SNP and overall. The F-statistics for each SNP were 
calculated by dividing the beta of the exposure squared by the standard error of the exposure 
squared; the overall F-statistic is the average of all the F-statistics of the SNPs. [76] The F-
statistic shows the strength of the instrument (F>10 suggests an instrument is not weak).  
Associations are presented as odds ratios (ORs) with 95% confidence intervals (CIs) and p-
values.  
For the third specific aim, the SNP of interest was searched using the PheWAS function in MR-
base [57] to identify other potential drug targets for TCZ, based on traits noted as associated with 
this SNP. The Bonferroni correction was used to account for multiple comparisons. The traits 
were aligned so that the minor allele was C for all traits to ensure appropriate direction of 
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association with the SNP among traits. PhenoScanner [80]was searched to identify the effect 
allele and its effect allele frequency (EAF).  
Statistical power and sample size  
The sample size for each aim were based on the available GWAS for exposure and outcome. 
Based on the large number of patients in each GWAS, it was expected that the results would be 
robust. MR is a powerful technique, and like all instrumental variable analyses, it requires large 
sample sizes. The sample size for an MR analysis is the sample size required for exposure and 
outcome divided by the r2 for genetic variants on exposure. The minimum detectable effect size 
based on available sample sizes was provided for the first two specific aims. [81] 
Study timeline  
The goal was to complete one final paper for each specific aim by mid-March 2020, with 
anticipated defense in May 2020. Specific timelines are as follows: 
Date Milestone Notes 
January 3, 2020 Post-defense dissertation proposal 
revision circulated to committee 
 
January 15, 2020 Draft of paper 1 circulated to 
committee for review 
Paper 1: Causal effect of RA on CD 
January 31, 2020 Comments expected from 
committee on paper 1 
 
January 31, 2020 Draft of paper 2 circulated to 
committee for review 
Paper 2: Causal effect of CD on RA 
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February 15, 2020 Comments expected from 
committee on paper 2 
 
February 29, 2020 Draft of paper 3 circulated to 
committee for review 
Paper 3: A Phenome-Wide 
Association Study to Assess 
Potential New Targets for 
Tocilizumab, an Interleukin-6 
Inhibitor 
March 15, 2020 Comments expected from 
committee on paper 3 
 
January 31-April 15, 2020 Revision to papers 1-3; submission 
of revised full dissertation draft to 
committee for review 
 
May 7, 2020 Final comments received from 
committee 
 
May 15, 2020 Dissertation defense  
 
Generalizability  
The results of these MR analyses are expected to have external validity, because there is no 
reason to think the causes of these diseases act via mechanisms that are population specific, 
although specific causes may be more relevant in some populations that others. [82] 
Limitations   
There are limitations to the MR method. First, the method relies on strong assumptions which 
can be difficult to verify empirically. This method required genetic instruments that predict the 
outcomes; GWAS have provided such instruments for both IMIDs and for a proxy of 
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tocilizumab. Second, genetic variants may have only a small effect on these diseases, which 
could introduce bias due to weak instruments, which were checked via the F-statistic. [83, 84] 
Additionally, effect size (small or otherwise) may not correspond to clinical significance, nor 
indicate effects of a clinical intervention at a future time, either due to the importance of 
cumulative exposure or time-dependent exposure. [64] Third, confounders of genetic variants on 
exposure may exist, typically as a result of population stratification; therefore, a homogeneous 
population is generally necessary for MR studies, with correction for population stratification.  
The current study used GWAS that primarily include people of European descent. Fourth, 
pleiotropy is another possibility; the instrument(s) should only impact the outcome through the 
exposure. The potential for pleiotropy requires sensitivity analyses. Fifth, RA and Crohn’s are 
more common in women than men, however sex-specific analysis is not usually possible using 
summary data. Sixth, MR studies usually require extremely large sample sizes; this is typically 
addressed by the very large sample sizes in GWAS, though for some studies it can be 
challenging to include sufficient numbers of cases, depending on the prevalence of the disease 
and method of disease ascertainment. Finally, an important current limitation of MR studies is 
that they address causal factors of disease incidence, but not issues related to disease 
progression; studies of disease progression and studies of patients are open to selection bias 
because they are missing those who have already died because of the exposure or because of 
competing risk of the outcome. [83, 84] 
PheWAS also have limitations. They are hypothesis-generating only; other studies such as 
randomized controlled trials are still required to confirm the effect suggested in a PheWAS.  A 
Bonferroni correction for statistical significance may not be appropriate if the traits are not 
independent from each other. Differences across populations could affect both the expected 
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allele frequency for the minor allele (which can vary by population) and also access of different 
populations to medical care from which diagnosis and ultimately identification of traits in a 
PheWAS are possible. [85] 
Human subjects protections 
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Figure 1.1. Directed Analytic Graph (DAG) showing Mendelian Randomization as an 








Chapter 2: An Assessment of Potential Causal Pathways Between Two Autoimmune 
Diseases: a Mendelian Randomization Study of Rheumatoid Arthritis as an antecedent and 




Rheumatoid arthritis (RA) and Crohn’s disease (CD) are two among a group of immune-
mediated inflammatory diseases (IMIDs). These diseases are common, collectively affecting as 
many as two million Americans, and cause significant pain and disability. These and other 
IMIDs may co-occur in patients, and patients with one IMID may have an increased risk of 
another IMID. Although these diseases may share at least one common cause (e.g., tumor 
necrosis factor-alpha overexpression), it is not clear is whether the co-occurrence of a second 
IMID is caused by the existence of the first IMID. 
Methods 
A two-sample Mendelian randomization study was conducted to assess the possible causal effect 
of RA on CD. The primary analysis used the inverse variance weighted (IVW); sensitivity 
analyses include weighted median, MR-Egger, and MR-PRESSO (Pleiotropy RESidual Sum and 
Outlier) methods. Genetic predictors of RA obtained from a GWAS including 22 studies with 
participants from European and Asian backgrounds, with 19,234 cases and 61,565 controls, were 
applied to summary genetic associations for CD, from the International IBD Genetics 
Consortium (IIBDGC), (17,897 cases, 33,977 controls) of European descent.  
Results  
All four analyses showed a protective effect of RA on CD. (IVW odds ratio [OR] 0.89, 95% 
confidence interval [CI] 0.77-1.00, p=0.042; MR-Egger OR 0.71, 95% CI 0.50-0.93, p=0.004; 
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weighted median OR 0.78, 95% CI 0.72-0.84, p=8.4x10-15; MR-PRESSO OR 0.92, 95% CI 
0.84-1.00, p= 0.047).  
Conclusions 
These analyses suggest that RA protects from the development of Crohn’s disease. It is possible 
this is due to issues with the data sources, or the infrequency of co-occurrence of the two 
diseases.  
Keywords 
















Rheumatoid arthritis (RA) and Crohn’s disease (CD) are two among a large group of immune-
mediated inflammatory diseases (IMIDs). Rheumatoid Arthritis (RA) is a common autoimmune 
disease characterized by pain and inflammation in the joints, leading to joint damage and 
significant loss of function. [16] Age of onset of RA is typically between 30 and 60 years. 
Estimates of the median age at disease onset range from 45-58 years. [17, 18] About 1.5 million 
Americans live with RA; [19] globally, 21 million people are affected. [5, 7] Crohn’s disease 
(CD) is an autoimmune disease characterized by abdominal pain, diarrhea, and fatigue, weight 
loss, fever, growth failure, anemia, or recurrent fistulas. [23] There are two peak age ranges for 
onset of CD. The first is from 15-29 years and the second is from 55-59 years. [24] In the U.S., 
between 593,000 to 780,000 people live with CD, with an estimated 33,000 new patients 
diagnosed each year; [4] globally, as many as 7 million people live with CD. [6]   
These IMIDs may co-occur, and it has been shown that patients with one IMID may have an 
increased risk of another IMID. The Danish National Patient Registry reported that the 
prevalence of co-occurrence of these two diseases  was 0.0027%. [87] A US-based commercial 
insurance claims database reported that co-occurrence of RA in CD patients was 1.7%. [88]  
What is not clear is whether the co-occurrence of a second IMID is caused by the existence of 
the first IMID. [8-10, 89] RA and CD have different clinical presentations but may have a 
common pathogenesis. Causes of these diseases are not well understood. An over-expression of 
tumor necrosis factor (TNF) may be one causal factor for IMIDs; [10] interleukin 6 (IL-6) has 
also been implicated, but there are likely other causes as well, and causality may be 
multifactorial in nature.   
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Mendelian Randomization (MR) has emerged as an important tool that facilitates causal 
inference from observational studies. This study design can allow for avoidance of a common 
problem in epidemiologic studies, confounding, [11]  because it takes advantage of the random 
allocation of genetic make-up at conception. MR compares disease status by genetically 
predicted exposure to obtain unconfounded estimates. MR implementation has been facilitated 
by the increasing availability of genome wide association studies (GWAS) genotyping millions 
of single nucleotide polymorphisms (SNPs). Other designs with similar properties exist, such as 
sibling or twin studies, but are not always feasible, whereas the investment in genetic studies has 
provided resources for MR. A number of MR studies have evaluated various potential causes of 
RA  (e.g., IL-5 [41, 42]; Vitamin D [43] [44];  linoleic acid [45]), while fewer have looked at CD 
(only abstracts were found, looking at IL-6 [46-48] and the GSDMB gene[49, 50]). No published 
MR studies were found that looked at these two IMIDs as potentially causally related. This study 
addresses the question of whether RA causes CD using a MR, which is an instrumental variable 
analysis with genetic variants as the instrument variable (IV).  
METHODS 
MR as instrumental variable analysis 
An instrumental variable should meet three conditions: relevance, exclusion-restriction and 
independence. Relevance indicates that the instrument is associated with the exposure. 
Exclusion-restriction indicates that the instrument affects the outcome only via effects on the 
exposure. Independence indicates that the instrument does not share common causes with the 
outcome. [60-62]  The assumptions are applied as follows in an MR study: the genotype (as the 
IV) must be associated with the phenotype/exposure disease (relevance), the genotype affects the 
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outcome disease only through the phenotype (exclusion-restriction), and there are no common 
causes (confounders) of the association between genotype and the outcome disease of interest.  
Data sources 
Genetic predictors of RA 
A large, curated GWAS of RA which includes 22 combined GWAS (18 studies including 
participants of European background, 4 studies including those of Asian background). The 
original data sources contained RA cases, of which 88.1% were seropositive for anti-citrullinated 
peptide antibody (ACPA), 9.3% were seronegative, and 2.6% had unknown antibody status. All 
RA cases had confirmed diagnosis according to the 1987 American College of Rheumatology 
criteria [65] or were diagnosed by a rheumatologist. The sample includes 19234 cases and 61565 
controls. Geographically matched controls were drawn from multiple sources, including an age-
related macular degeneration GWAS, a myocardial infarction GWAS, the UK 1958 birth cohort, 
the UK National Blood Services cohort, and non-autoimmune disease cases from the Wellcome 
Trust Case Control Consortium (WTCCC). [66, 67] 
Genetic associations with Crohn’s disease 
A large, curated GWAS of Crohn’s disease is the International IBD Genetics Consortium 
(IIBDGC), which combines data from six CD GWAS, all of European descent, including 17897 
cases and 33977 controls. Patients in the IIBDGC-consortium GWAS were enrolled in medical 
centers in the U.S. and Canada (Cedars-Sinai Medical Center; Johns Hopkins University; 
University of Chicago; University of Montreal; University of Pittsburgh; University of Toronto 
Genetics Research Centers); CD was physician diagnosed using x-rays, endoscopy reports, 
pathology reports, and other diagnostic tools. The GWAS included geographically matched 
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controls as well as additional age- and ethnicity-match controls from the New York Health 
Project. Comprehensive demographic data for all component GWAS were not found, but one 
component GWAS (Welcome Trust Case Control Consortium) reported median age of 
participants as 45.7 years among the WTCCC panel and 43.9 years among the replication panel, 
and 60% of participants were <age 50; however these participants represent only a small 
proportion of the total participants in the IIBDGC. [67-71, 90] 
Statistical analysis 
All SNPs identified as predictors of RA with significance p<5x10-8 were reviewed in 
PhenoScanner to ascertain potential pleiotropy. There are two types of pleiotropy: vertical and 
horizontal. Vertical pleiotropy occurs when a SNP has an effect on the outcome via a 
downstream effect. This in essence captures what MR does: it determines, with the SNP as the 
IV, whether an exposure has an effect on an outcome. Horizontal pleiotropy occurs when the 
SNP, as the IV, influences multiple diseases or traits, and thereby affects the disease independent 
of the exposure. [91] The PhenoScanner review was conducted to determine whether the SNPs 
predictive of RA are also associated with CD directly; this would suggest horizontal pleiotropy. 
A two-sample MR analysis was conducted. SNPs to predict RA were selected as having p-values 
below 5x10-8. Independent SNPs were selected as having r2 (correlation coefficient) threshold for 
identifying linkage disequilibrium as <0.001, suggesting independence between genetic variants 
predicting the exposure.[78, 79] The F-statistic was calculated for each SNP and overall [76] to 
show the strength of the instrument (F>10 suggests a strong instrument).   
The primary analysis used the inverse variance weighted (IVW) method with multiplicative 
random effects. Sensitivity analyses included weighted median, MR-Egger, and MR-PRESSO 
methods. The inverse variance weighted method combines Wald estimates for each SNP (ratio of 
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SNP on outcome to SNP on exposure) [74] using the first-term of Fieller’s theorem (variance of 
SNP on outcome divided by SNP on exposure) [75] to approximate the SNP-specific variance. 
This method assumes each included instrument fulfills the assumptions of an IV. Inclusion of 
pleiotropic SNPs may decrease the validity of this method. 
The additional methods were used as sensitivity analyses to determine whether the IV 
assumptions are violated or if one or more outlier SNPs is driving an effect estimate. These 
sensitivity analyses use different assumptions. A weighted median of the SNP-specific Wald 
estimates is valid as long as >50% of the weight is contributed by valid instruments. [76] MR-
Egger relaxes the assumption that there are no pleiotropic effects, but does not identify or correct 
for them. This method is robust to invalid instruments, but relies on the InSIDE assumption 
(INstrument Strength Independent of Direct Effect). [77] MR-PRESSO (Pleiotropy RESidual 
Sum and Outlier) identifies and removes outliers due to horizontal pleiotropy and tests 
differences in the estimates before and after this correction. The MR-Egger intercept p-value was 
reported because a significant intercept indicates that the IVW estimate may not be valid, and the 
MR-Egger I2 value was calculated to determine how much variation across the meta-analysis is 
due to heterogeneity. [92] MR-PRESSO requires that >50% are valid instruments. Removing 
outliers in this way leads to an unbiased estimate. [72, 73]   
The minimum effect size detectable with the current sample size, based on 80% power and 
significance 0.05, was calculated using code from Burgess, provided in Appendix 2. [93] 
The MR-base platform [57]and R version 3.6.1 (2019-07-05) [56] were used in this analysis. 
Protection of human subjects 
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Deidentified, publicly available summary data were used in this study; therefore Institutional 
Review Board approval was not required.  
RESULTS 
Forty-one independent SNPs were identified as predictors of RA (significance p<5x10-8). These 
SNPs were reviewed in PhenoScanner [80]; all 41 SNPs are located on different genes, and 
horizontal pleiotropy was found, as five SNPs were also predictive of Crohn’s disease: rs168962, 
rs212389, rs34536443, rs6679677, and rs9747973. On additional SNP was also associated with 
inflammatory bowel disease (rs9296009). Most of the RA-associated SNPs were associated with 
multiple other traits. Many were associated with other autoimmune diseases (e.g., allergic and 
celiac diseases) as well as an assortment of other diseases and traits (e.g., height, coronary artery 
disease, hypothyroidism). Table 2.1 lists characteristics of these 41 SNPs. 
The inverse variance weighted analysis indicated that RA is associated with a reduced risk of 
Crohn’s disease (OR 0.89, 95% CI 0.77-1.00, p=0.042). Both the MR-Egger analysis and the 
weighted median analyses also suggest reduced risk of CD in RA patients (MR-Egger OR 0.71, 
95% CI 0.50-0.93, p=0.004; weighted median OR 0.78, 95% CI 0.72-0.84, p=8.4x10-15). The 
scatter plot (Figure 2.1) shows that the MR-Egger line missed the origin, and the intercept was 
significant, suggesting that the IVW estimate is not valid.  For this reason, an MR-PRESSO 
analysis was conducted to evaluate the effect of eliminating outliers. The MR-PRESSO analysis 
also suggested a reduced risk of CD in RA patients (OR 0.92, 95% CI 0.84-1.00, p= 0.047).  
MR-PRESSO identified 15 SNPs as outliers potentially causing horizontal pleiotropy; this 
included the six identified via PhenoScanner with known associations with CD or inflammatory 
bowel disease, plus an additional 9 SNPs. The MR-PRESSO result suggests that even after 
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eliminating these 15 outlier SNPs, this decreased risk remains statistically significant. Table 2.2 
summarizes the results of the four analyses. 
The F-statistic was calculated by dividing the squared beta of the exposure by the squared 
standard error of the exposure; the F-statistic average was 129, suggesting strong instruments (all 
F-statistics for individual SNPs were >10).  
A calculation was performed using R [56] to determine the minimum effect size detectable given 
the available sample size. Assumptions in this calculation were as follows: 80% power, 
significance (alpha)=0.05, and the ratio of cases to controls (17,897 and 33,977, respectively) is 
0.53. The minimum effect detectable with the available sample size and 80% power was 0.108, 
corresponding to an odds ratio of 1.11, which would represent an increased odds of CD in RA, or 
0.90, which would represent a decreased odds of CD in RA. The R code for this calculation is 
provided in Appendix 1. 
DISCUSSION 
This MR study suggests that a decreased risk of CD in RA patients. With strong instruments as 
shown by high F-statistics, the assumptions for the primary and sensitivity analyses were met; 
even the removal of a substantial (but less than 50%) proportion of SNPs as potential outliers in 
the MR-PRESSO analysis yielded a significant result.  
Co-occurrence of RA and CD vs co-occurrence of IMIDs 
It is surprising that one IMID would be associated with a lower risk of another IMID, 
particularly in light of claims databases showing co-occurrence of IMIDs A study of two large 
commercially insured patient populations (US-based) reported co-occurrence of (any) IMIDs in 
9.1-9.8% of patients. These datasets excluded Medicare and pension plan enrollees, suggesting 
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this may be a low estimate, based on the age distribution of some IMIDs, which have older ages 
of onset. [8] However, contrary to an almost 10% co-occurrence of any two IMIDs, the Danish 
National Patient Registry reported very low of co-occurrence of RA and CD specifically 
(0.0027%) [12], and a US-based commercial insurance claims database reported substantially 
higher (but still low) co-occurrence of RA and CD (1.7%.) [13] It seems that other IMIDs may 
co-occur, but not specifically RA with CD. There are, however, biases inherent in US-based 
commercial insurance database studies that could suggest underreporting of RA and CD. The age 
distribution of participants in these plans may be younger than the general population, and 
healthier (healthy enough to work, though immediate family members are typically also 
covered). Older patients (typically covered by Medicare rather than commercial insurance) are 
generally more likely to have an RA diagnosis, so these data sources may miss some overlap 
between RA and CD populations.  
RA treatments potentially causing CD, in opposition to current MR results 
Some treatments for RA could actually cause Crohn’s disease. For example, there have been 
reports of Crohn’s disease following use of non-steroidal anti-inflammatory drugs (NSAIDs), 
which used to be the first-line treatments for RA. [94]  There are also biological mechanisms by 
which more recent drugs may cause autoimmunity. A receptor antagonist could lead to increases 
in other cytokines, which could cause another IMID in an RA patient taking a TNF-a inhibitor 
such as infliximab or etanercept. Treatment of an autoimmune disease may also unmask another 
untreated, subclinical disease. This has been seen infrequently in RA and CD patients whose 
treatment with a TNF-a inhibitor has led to a demyelinating disorder that mimics early multiple 




Role of interleukin-6 (IL-6)]and tumor necrosis factor-alpha (TNF-a) inhibition 
It is difficult to identify reasons that RA should be protective for CD. There are thought to be 
multiple common contributing causes of these diseases, including IL-6 and TNF-a 
overexpression. A possibility is that treating this overexpression of a causal cytokine could 
simultaneously treat diagnosed RA and preemptively treat subclinical CD, which could prevent 
CD from being clinically diagnosed. As some medications are approved for the treatment of both 
RA and CD (e.g., adalimumab, marketed as Humira by Abbvie), [31] a shared causal pathway 
makes sense. This might suggest that the SNPs identified as causal for RA were actually causal 
for response to treatment for RA and not directly causal for RA itself. This was not assessed in 
this analysis.  
Further differences between RA and CD 
Finally, RA and CD are both disorders of the immune system, but they have different relations 
with cancer.  Both women and men with RA have lower incidence of some cancers compared to 
the general population (e.g., in women, breast, ovary, uterus, cervix, colon/rectum, and 
melanoma and in men, prostate and colon/rectum) and similar incidence of many other cancers 
(e.g., in both women and men, stomach, pancreas, bladder, kidney, thyroid, brain/CNS, and 
myeloma; in women additionally, esophagus, liver, and Hodgkin’s disease and in men 
additionally melanoma), compared to the general population. Incidence of a few cancers were 
increased (in women and men, lung, non-Hodgkin’s lymphoma, and leukemia, and in men only, 
esophagus and liver), compared to the general population. [96]  Patients with CD have increased 
risk of multiple types of colorectal cancers, Hodgkin’s disease, lymphoma, melanoma, non-
melanoma skin cancer, and cervical cancer in women. [97] Mortality from cancer is similar in 
RA patients compared to the general population; [22] mortality from cancer is higher in CD 
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patients compared to the general population. [27] These findings suggest that RA is more the 
result of a very vigilant immune system, whereas CD this vigilance does not appear to be evident 
for CD either because RA and CD represent different disorders of the immune system or because 
CD specifically pre-disposes to certain cancers.  A distinction has been suggested between 
autoinflammatory diseases (AIDs) and autoimmune diseases (AD), of which CD is classified as 
one of the former and RA as one of the later. [98] Different pathogenic triggers and 
inflammatory processes may exist, but it is not clear whether these are clinically (or otherwise) 
useful distinctions. 
Data sources 
The most feasible reason for this surprising result is the role of bias related to the data source(s). 
The age distributions of the two data sources were not fully provided. Since RA is often 
diagnosed at an older age than CD, [17, 18, 24] if patients enrolled in the GWAS with diagnosed 
RA but without having been diagnosed with CD, then those participants may have been unlikely 
ever to develop CD. This could lead to the lower risk of CD in those patients as seen in this MR 
study; that it is not a mechanistic protective effect of RA, but a function of people diagnosed 
with RA but not CD having enrolled in the GWAS. 
It is also unclear whether controls in each data source were “healthy controls” (e.g., free from the 
“other” disease), or if they represented the underlying cohort form which cases were drawn. In 
the former case, such an omission of RA patients in the CD data set and CD patients in the RA 
data set would underestimate the association seem between the diseases and could affect the 
direction of the association.  
Protective effect of RA on CD 
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It is possible that these results are not due to issues related to the data sources and that having 
RA is truly protective for CD. A biological mechanism for this is not clear and would require 
further research. 
Strengths and limitations 
There are limitations to the MR method. First, the method relies on strong assumptions which 
can be difficult to verify empirically. This method requires a genetic instrument that predicts the 
outcome. GWAS have provided such instruments for RA. Genetic variants may have only a 
small effect on these diseases, which could introduce bias due to weak instruments. [83, 84] The 
41 instruments were strongly associated with the exposure, based on F-statistics well over 10 
(individually and overall). Second, confounders of genetic variants on exposure may exist, 
typically as a result of population stratification; therefore, a homogeneous population is generally 
necessary for MR studies, with correction for population stratification, [83, 84] as used here. 
Third, with regard to the exclusion-restriction assumption, the MR-PRESSO analysis suggests 
some horizontal pleiotropy. However, estimates were the same after removing 15 outliers. The 
low MR-Egger I2 value of 8.30% suggests low heterogeneity across the SNPs included in the 
MR-Egger analysis. Fourth, effect size (small or otherwise) may not correspond to clinical 
significance, nor indicate effects of a clinical intervention at a future time, either due to the 
importance of cumulative exposure or time-dependent exposure. [64] Fifth, RA and Crohn’s are 
more common in women than men, however sex-specific analysis is not publicly available. 
Sixth, MR studies usually require extremely large sample sizes; this is typically addressed by the 
very large sample sizes in the GWAS used in this study; there were 19234 cases and 61565 
controls in the RA dataset and 17897 cases and 33977 controls in the CD dataset, and the study 
was well-powered to detect the protective effect of RA on CD (power=0.88).  
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Finally, an important current limitation of MR studies is that they can only address causal factors 
of disease incidence, but not issues related to disease progression; studies of disease progression 
and studies of patients are open to selection bias because they are missing those who have 
already died because of the exposure or because of competing risk of the outcome. [83, 84] 
CONCLUSION 
This Mendelian randomization study determined that rheumatoid arthritis is associated with a 
reduced risk of Crohn’s disease. Further study would be required to better understand several this 
result, in particular, a biological mechanism that would cause patients with RA to be less likely 
to develop CD. However, it is highly possible that this result was driven by bias due to the age of 
the exposure population; participants who developed RA without having first developed CD may 
be unlikely ever to do so. 
KEY MESSAGES 
• Mendelian randomization is a powerful method that can determine causal relationships 
between exposures and outcomes, if appropriate instruments can be identified. 
• Although IMIDs often co-occur, RA and CD co-occur infrequently. 
• This MR study showed that RA is protective for CD; however, an underlying mechanism 
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Table 2.1. SNPs identified in MR-base as associated with RA (p<5x10-8), and their location 
as determined in PhenoScanner. [80] Rows highlighted in yellow were identified as outliers 
and removed in the MR-PRESSO analysis; red text indicates SNPs identified as associated 














































Table 1.2. Mendelian randomization association of RA on CD, based on 34 independent 
SNPs* (p-values all <5x10-8).  









MR-Egger 0.71 0.50-0.93 0.004 386.7 (0) 0.028 8.30% 
Weighted median 0.78 0.72-0.84 8.4E-15       
Inverse variance weighted 0.89 0.77-1.003 0.042 451.0 (0)     
MR-PRESSO  0.92 0.84-1.00 0.047       
*34 of 41 SNPs were included in the IVW, weighted median, and MR-Egger analyses; 7 SNPs were palindromic 

















Figure 2.1. Scatter plot of IVW, MR Egger, and weighted median analyses showing effect 













Chapter 3: An Assessment of Potential Causal Pathways Between  Two Autoimmune 
Diseases: a Mendelian Randomization Study of whether Crohn’s Disease as an antecedent 




Rheumatoid arthritis (RA) and Crohn’s disease (CD) are two immune-mediated inflammatory 
diseases (IMIDs), together affecting as many as two million Americans. These diseases cause 
significant pain and disability. Studies show that two or more IMIDs may co-occur in patients. 
RA and CD may share several common causes (e.g., tumor necrosis factor-alpha overexpression, 
excess interleukin 6), but it is not clear if CD itself causes rheumatoid arthritis.   
Methods 
A two-sample Mendelian randomization study was conducted to assess a possible causal role of 
CD on RA. The primary analysis used inverse variance weighting (IVW) to determine the effect 
of CD on RA. Sensitivity analyses included weighted median, MR-Egger, and MR-PRESSO 
(Pleiotropy RESidual Sum and Outlier). Genetic predictors of CD from summary statistics from 
the International IBD Genetics Consortium (IIBDGC), (17,897 cases, 33,977 controls of 
European descent) were applied to a GWAS of RA that included 22 studies including patients of 
European and Asian backgrounds (19,234 cases, 61,565 controls).  
Results  
The primary analysis and all three sensitivity analyses showed no causal effect of CD on RA 
(IVW odds ratio [OR] 0.97, 95% confidence interval [CI] 0.88-1.07, p=0.59; weighted median 
OR 0.98, 95% CI 0.94-1.03, p=0.49; MR-Egger OR 0.92, 95% CI 0.67-1.18, p=0.54, MR-




These analyses suggest that CD does not cause rheumatoid arthritis. Co-occurrence of CD and 
RA is fairly uncommon, and when it does occur, may be due to shared causes of both conditions 
such as overexpression of TNF-a or IL-6.  
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Crohn’s disease (CD) and Rheumatoid Arthritis (RA) are two among a large group of immune-
mediated inflammatory diseases (IMIDs). Crohn’s disease (CD) is characterized by abdominal 
pain, diarrhea, fatigue, weight loss, fever, growth failure, anemia, or recurrent fistulas. [23] Age 
of onset of CD peaks at age 15-29 years and again at 55-59 years. [24] In the U.S., it is estimated 
that 593,000 to 780,000 people live with CD, with an estimated 33,000 new cases per year. [4], 
and prevalence estimates range from 0.1%-0.15%. [99, 100]  Rheumatoid Arthritis (RA) is a 
common autoimmune disease characterized by pain and inflammation in the joints. [16] 
Estimates of median age of onset in the US range from 45 years in women/50 years in men  [18] 
to 58 years overall. [17] Estimated prevalence of RA in the US is 0.72% (95% CI 0.66–0.77), 
with RA affecting about 1.5 million Americans. [19]  
IMIDs often co-occur, patients with one IMID may have a higher risk of developing another 
IMID. A study using two claims databases, the IMS Health Integrated Administration Claims 
Database and the Market Scan Commercial Claims and Encounters Database, evaluated the co-
occurrence of CD and other IMIDs between 2001 and 2002. In both datasets, there was an 
increased risk of RA in CD patients (in MarketScan, OR 2.37, 95% CI 2.02-2.77; in IMS Health, 
OR 2.76, 95% CI 2.40-3.18). [9] The Danish National Patient Registry reported increased risk of 
rheumatoid arthritis in CD patients (OR 2.1; 95% CI 1.6-2.8) [101] but also reported a very low 
prevalence of co-occurrence of these two diseases (0.0027%) [87] A US-based commercial 
insurance claims database also reported increased risk of RA in CD patients (OR 1.9, 95% CI 
1.5–2.3); prevalence of RA in CD patients was 1.7%. [88]   
RA and CD have different clinical presentations but may share several common causes. Various 
cytokines have been implicated in the development of CD, RA, and other autoimmune diseases; 
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an over-expression of tumor necrosis factor (TNF) may be one causal factor; [10] interleukin 6 
(IL-6) [41, 89, 102] and interleukin 23 (IL-23) [103] have also been implicated. Causality is 
likely multifactorial, due to multiple risk factors, of which none appears to be a necessary cause. 
[104] Different cytokine targets of different treatments also suggests multiple causal pathways. 
Tumor necrosis factor alpha (TNF-a) inhibitors include etanercept (Enbrel, marketed by Pfizer), 
[54] infliximab (Remicade, marketed by Janssen), [105]and adalimumab (Humira, marketed by 
AbbVie); [31] interleukin-6 (IL-6) inhibitors include tocilizumab (Actemra, marketed by 
Genentech) [106] and sarilumab (Kevzara, marketed by Regeneron and Sanofi). [107]  
The public health impact of each of these two diseases is substantial The Global Burden of 
Disease study reported YLDs (years lived with disability) at 335,400 for CD. [14] In a review of 
Health-Related Quality of Life (HQOL) studies, compared to healthy controls, CD patients 
scored worse on physical, social, and emotional function. Compared to patients with ulcerative 
colitis, patients with CD scored similar to or worse on general HQOL measures. [40] Estimated 
direct costs of CD in 1998 (including inpatient and outpatient visits and pharmacy) were $708 
million; indirect costs were estimated at $75 million and included costs associated lost 
productivity. [41] People with RA are at risk for falls and other injuries and may be unable to 
work. [37] One estimate of health care costs attributable to RA in 2013 was $140 billion. [38] 
The National Health Interview Survey (NHIS) reported that 43.5% of individuals with RA had 
limitations to activity related to their RA. [39] In the Global Burden of Disease 2010 study, RA 
was ranked as the 42nd highest contributor to global disability, and YLDs were 55 per 100,000 
population (in 2010), and higher in females than in males (87.84 per 100,000 versus 22.46 per 





If CD is a causal factor in RA, then these impacts are magnified. To date, it has not been 
established whether CD is a causal factor in developing RA. If it is determined that CD is a cause 
of RA, then the importance of adequately treating CD to prevent the additional pain, disability, 
and costs associated with RA is clear. 
Mendelian Randomization (MR) is a method that facilitates causal inference from observational 
studies. This study design bypasses confounding, which is a common problem in epidemiologic 
studies, [11] by taking advantage of the random allocation of genetic material at conception. MR 
compares disease status by genetically predicted exposure to obtain unconfounded estimates of 
association. The method is supported by available genome wide association studies (GWAS) 
genotyping millions of single nucleotide polymorphisms (SNPs). Other study designs which take 
advantage of genetics to avoid confounding, including sibling or twin studies, are not always 
feasible, so the increasing availability of genetic studies has supported the growth of the MR 
method.  
Few MR studies have evaluated causes of CD.  A review of the literature identified only five 
abstracts, which looked at IL-6 [46-48] and the GSDMB gene [49, 50] as potential causal factors 
of CD. On the other hand, a search for MR studies and RA yielded 61 results, many of which 
have evaluated various potential causes of RA. For example, decreased levels of IL-6 may be 
linked to an increased risk of RA. [41, 42] One study found no effect of vitamin-D associated 
SNPs on risk of RA. Another found one vitamin D SNP associated with a poorer response to 
TNF-alpha inhibitor therapy in RA patients. [43, 44] An MR study found an inverse effect of 
linoleic acid and RA. [45] 
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No published MR studies were found that looked at these two IMIDs as potentially causally 
related. Given the limited data available on the causal relationship between CD and RA, and the 
public health importance with respect to causality, this study seeks to address the question of 
whether CD causes RA using an MR study.  
METHODS 
MR as instrumental variable analysis 
MR is an instrumental variable analysis with genetic variants as the instrument variable (IV). An 
instrumental variable is used to assess the effect of an exposure on an outcome when the 
exposure is open to confounding.  Three conditions are necessary to satisfy an instrumental 
variable. Relevance means that the chosen instrument is associated with the exposure. Exclusion-
restriction means that the instrument’s effect on the outcome work only through its effects on the 
exposure. Independence means a lack of confounding between the instrument and the outcome.  
[60-62]   
Data sources 
Genetic predictors of Crohn’s disease 
The International IBD Genetics Consortium (IIBDGC) is a large, curated GWAS of CD. This 
GWAS combines data from six CD GWAS, with 17,897 cases and 33,977 controls.  All GWAS 
participants are of European descent. Participants were enrolled in medical centers in the U.S. 
and Canada, and Europe. Disease ascertainment was by physicians using typical diagnostic tools 
(e.g., x-rays, endoscopy reports, pathology reports). Geographically matched controls were 
included, as were age- and ethnicity-match controls from the New York Health Project. [67-71] 
Comprehensive demographic data for all component GWAS were not found, but one component 
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GWAS (Welcome Trust Case Control Consortium) reported median age of participants as 45.7 
years among the WTCCC panel and 43.9 years among the replication panel, and 60% of 
participants were <age 50; however these participants represent only a small proportion of the 
total participants in the IIBDGC. [67, 90] 
Genetic associations with RA 
The data source for RA included 22 combined GWAS, of which 18 studies included participants 
of European background and 4 studies included those of Asian background.  RA cases were 
physician diagnosed according to the 1987 American College of Rheumatology criteria or 
similar criteria as ascertained by a rheumatologist. The sample includes 19,234 cases and 61,565 
controls. [65, 66]  
Statistical analysis 
All SNPs identified as predictors of CD with significance p<5x10-8 were reviewed in 
PhenoScanner to ascertain potential pleiotropy. There are two types of pleiotropy: vertical and 
horizontal. Vertical pleiotropy occurs when a SNP has an effect on the outcome that has an effect 
downstream of the exposure. This in essence captures what MR does: it determines, with the 
SNP as the IV, whether an exposure has an effect on an outcome. Horizontal pleiotropy occurs 
when the SNP, as the IV, influences multiple diseases or traits independent of the exposure. [91] 
The PhenoScanner review was conducted to determine whether the SNPs predictive of CD are 
also associated with RA; this would suggest horizontal pleiotropy. 
A two-sample MR analysis was conducted. SNPs to predict CD were selected with p-values 
below 5x10-8. Independent SNPs were selected as having r2 (correlation coefficient) threshold for 
identifying linkage disequilibrium as <0.001, to obtain independent genetic variants predicting 
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the exposure.[78, 79] The F-statistic was calculated for each SNP and overall [76] to show the 
strength of the instrument (F>10 suggests a strong instrument).  All SNPs identified as predictive 
of CD were searched using PhenoScanner [80], a comprehensive, curated genotype to phenotype 
cross-reference, to assess the potential for horizontal pleiotropy. 
The primary analysis used the inverse variance weighted (IVW) method with multiplicative 
random effects. Sensitivity analyses included weighted median, MR-Egger, and MR-PRESSO 
methods. The inverse variance weighted method meta-analyzes Wald estimates for each SNP 
(ratio of SNP on outcome to SNP on exposure) [74] using the first-term of Fieller’s theorem 
(variance of SNP on outcome divided by SNP on exposure) [75] to approximate the SNP-
specific variance. This method assumes each included instrument fulfills the assumptions of an 
IV. Inclusion of pleiotropic SNPs may decrease the validity of this method. 
Three additional methods were used as sensitivity analyses to determine whether the IV 
assumptions were violated or if outlier SNPs were driving an effect estimate. These sensitivity 
analyses use different assumptions. A weighted median of the SNP-specific Wald estimates is 
valid as long as >50% of the weight is contributed by valid instruments. [76] MR-Egger relaxes 
the assumption that there are no pleiotropic effects, but does not identify or correct for them. 
This method is robust to invalid instruments, but relies on the InSIDE assumption (Instrument 
Strength Independent of Direct Effect) [77], which states that the strength of the association 
between the IV (SNP) and the exposure should be independent of pleiotropic effects. This can be 
considered relaxing the exclusion-restriction IV assumption. [108]  The MR-Egger intercept p-
value was reported, because a non-zero intercept indicates that the IVW estimate may not be 
valid. The MR-Egger I2 value was calculated to identify the percentage of total variation across 
the meta-analysis that is due to heterogeneity. [92] The third sensitivity analysis, MR-PRESSO 
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identifies and removes outliers due to horizontal pleiotropy and tests differences in the estimates 
before and after this correction. MR-PRESSO requires that >50% are valid instruments. 
Removing outliers in this way leads to an unbiased estimate. [72, 73] 
The minimum effect size detectable with the current sample size, based on 80% power and 
significance 0.05, was calculated using code from Burgess, provided in Appendix 2. [93] 
The MR-base platform [57] and R version 3.6.1 (2019-07-05) [56] were used in this analysis. 
Protection of human subjects 
Deidentified, publicly available summary data were used in this study. Institutional Review 
Board approval was not required.  
RESULTS 
Table 3.1 shows 121 independent SNPs identified as predictors of Crohn’s disease (significance 
p<5x10-8). These SNPs were reviewed in PhenoScanner [80] for potential pleiotropy. Horizontal 
pleiotropy is suggested, as 16 SNPs identified as causal for CD were also predictive of RA.  Of 
these, 15 were among the 21 excluded in the MR-PRESSO sensitivity analysis. Most of the CD-
associated SNPs were associated with multiple other traits. Many were associated with other 
autoimmune diseases (e.g., allergic and celiac diseases, psoriasis, type 1 diabetes mellitus) as 
well as an assortment of other diseases and traits (e.g., height, body mass index, and various 
blood cell counts).  However, these factors are not though to cause RA. 
The inverse variance weighted analysis and all sensitivity analyses were null (IVW OR 0.97, 
95% CI 0.88-1.07, p=0.59; weighted median OR 0.98, 95% CI 0.94-1.03, p=0.49; MR-Egger OR 
0.92, 95% CI 0.67-1.18, p=0.54; MR-PRESSO OR 1.00; 95% CI 0.64-1.36, p=0.90). The MR-
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Egger intercept was not significant. The MR-PRESSO analysis identified and eliminated 21 
outliers out of 121 SNPs.  
Table 3.2 summarizes the results of the four analyses. 
The F-statistic was calculated by dividing the squared beta of the exposure by the squared 
standard error of the exposure; the F-statistic average was 90 and all F-statistics for individual 
SNPs were >10.  
A power calculation was performed using R [47] to determine the minimum effect size 
detectable given the available sample size. Assumptions in this calculation were as follows: 80% 
power, significance (alpha)=0.05, and the ratio of cases to controls (19,234 and 61,565, 
respectively) is 0.312. The minimum effect detectable with the available sample size and 80% 
power was calculated to be 0.05, corresponding to an odds ratio of 1.05. The R code for this 
calculation is provided in Appendix 2. 
DISCUSSION 
The review of 121 SNPs predictive of CD in PhenoScanner [80] suggested some amount of 
horizontal pleiotropy, as 16 SNPs identified as causal for CD were also predictive of RA. 
However, 15 of these 16 pleiotropic SNPs were removed in the MR-PRESSO analysis, yet the 
null result persisted. The assumption of >50% valid instruments was met for all three sensitivity 
analyses, based on these MR-PRESSO findings. The F-statistic suggested strong instruments. 
The observed effect sizes were below the minimum effect size detectable based on sample sizes. 
Selection bias 
Selection bias may be a factor that has prevented this MR study from identifying a causal 
relationship between CD and RA. CD is has two peak age ranges for diagnosis, and the first is 
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several decades younger than the second, which is closer to the average age of onset for RA. [17, 
18, 24] The average age of all participants in the full CD GWAS was not found, but one of the 
component GWAS reported that 60% of participants were under age 50. [67] Therefore, is 
possible that patients were enrolled in the CD GWAS prior to an age of RA diagnosis. This 
would suggest that RA could not be detected in the analysis because there were too few GWAS 
participants with an RA diagnosis simply due to their age. A different dataset with an age 
distribution skewed older may have yielded a different result.  
Non-RA extra-intestinal manifestations of CD 
This MR study suggests that CD does not cause RA.  While CD patients commonly experience 
joint pain and arthropathies, these extra-intestinal manifestations of Crohn’s disease differ from 
RA. The arthritis experienced by CD patients is primarily peripheral oligoarthritis, affecting 
fewer than 5 joints and most commonly affecting large joints such as hips, knees, wrists, ankles, 
and elbows. About 1-6% of patients develop ankylosing spondylitis, which usually affects 
sacroiliac joints and spine and may lead to spinal fusion.  Peripheral arthritis differs from 
rheumatoid arthritis; RA is progressive and deforming, ultimately destroying joints, while 
arthritis associated with CD does not cause long-term joint damage. [109] Peripheral arthritis is 
commonly described in CD patients; studies suggest it may occur in nearly a third of CD 
patients, though estimates were lower in Norway. [110-112] Onset of arthritic symptoms may 
precede bowel symptoms in patients with CD. Prognosis is generally good in CD patients due to 
the non-progressive/non-erosive nature of this type of arthritis. [113]  
Shared etiology 
Different clinical presentation of CD and RA does not preclude a shared etiology. A number of 
issues point toward shared etiology: familial clustering, co-occurrence of IMIDs, and efficacy of 
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treatments across these diseases. GWAS, including those used in the current MR study, show 
some overlap in SNPs predicting both CD and RA, which also suggests a shared pathogenesis. 
While each SNP may have a small effect individually, each SNP disrupts the immune system to 
alter risk of disease without individually causing disease alone. [114]  
TNF-alpha 
Dysregulation of the immune system caused by inflammatory cytokines including TNF-a has 
been shown to cause CD and RA as well as other IMIDs. [10] TNF is a cytokine that regulates 
inflammatory reactions and immune functions by controlling cell proliferation, differentiation, 
and cell death, and is important in the pathogenesis and pathology of both RA and CD. [10] 
Preclinical studies in RA have shown that the concentration of TNF at inflammation sites is 
associated with disease activity, which suggested the early hypothesis that removing excess TNF 
would provide clinical benefit, [115, 116] and further preclinical studies identified the benefit of 
TNF-a inhibition specifically. [117, 118] Subsequent regulatory approval of TNF-alpha 
inhibitors such as etanercept, infliximab, and adalimumab to treat RA [31, 54, 105] have 
supported the clinical therapeutic benefit of TNF-a inhibition in many of these patients. In CD, 
high TNF levels are seen in inflamed mucosa of patients, [119] and animal studies have shown 
TNF levels to correspond to disease activity. [120, 121] As with RA, inhibition of TNF can 
reduce disease activity or severity, [122] and approval of two of the TNF-a inhibitors, infliximab 
and adalimumab, [31, 105] support the clinical benefit of inhibition of TNF-a in CD patients.  
Interleukin-6 
IL-6 is a cytokine that induces protein synthesis in hepatocytes, and increased serum IL-6 has 
been seen in acute conditions including surgery, burns, and infections, as well as in chronic 
conditions, such as CD and RA. Serum IL-6 concentrations were found to be higher in CD 
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patients than in healthy controls, and a nonsignificant trend was found toward higher serum IL-6 
in CD patients with active disease versus inactive disease. [102]  In RA patients, the IL-6 -
174G/C variant has been associated with RA in both European and Asian populations. [41] IL-6 
promotes joint inflammation through vascular endothelial growth factor (VEGF), levels of which 
are associated with RA disease activity. IL-6 is found in synovial fluid and serum of RA patients, 
with levels corresponding to disease activity and joint damage. Serum IL-6 levels were elevated 
in RA patients compared to controls, and higher levels were associated with more severe disease 
activity as measured by the DAS28. [123] 
Co-occurrence of disease 
While as many as 9.1-9.8% of patients with one IMID may also have a second IMID, [8] CD and 
RA co-occur far less frequently than that. An increased risk of RA in CD patients has been 
reported, which supports the idea of shared etiology, though co-occurrence of CD and RA is still 
low. The increased risk of RA in CD patients reported in the Danish National Patient Registry 
(OR 2.1; 95% CI 1.6-2.8) and the co-occurrence of CD and RA was seen in 0.0027% of patients. 
The authors suggested that the microbiome of the gut may have triggered RA, and they suggest a 
shared causal role of T-helper cells TH1 and TH17 in both CD and RA. [87, 101] The increased 
risk of RA in CD patients reported in a US-based commercial insurance claims database (OR 
1.9, 95% CI 1.5–2.3; RA seen in 1.7% of CD patients) was attributed to possible common 
genetic or environmental causes, but the mechanism was not described. [88] Another study using 
US claims data also found increased risk of RA in CD in both databases (in MarketScan, OR 
2.37, 95% CI 2.02-2.77; in IMS Health, OR 2.76, 95% CI 2.40-3.18 ), and the authors suggest a 
shared underlying pathogenic mechanism due to immune system dysfunction, without providing 
additional clarification on that mechanism. There are, however, biases inherent in US-based 
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commercial insurance database studies that could suggest underreporting of RA and CD. The 
participants are generally healthier than the general population (healthy enough to work). The 
age distribution of participants in these plans may be younger than the general population, since 
commercial insurance plans are generally tied to employment; older patients, typically covered 
by Medicare rather than commercial insurance, are generally more likely to have an RA 
diagnosis. Therefore, commercial insurance claims data may miss some overlap between RA and 
CD populations. [9]  
Strengths and limitations 
There are limitations to the MR method, which may have impacted the validity of these results. 
First, the method relies on strong assumptions ; for example, that the genetic instruments 
strongly predict the exposure [83, 84] However, all 121 instruments were strongly associated 
with the exposure, based on F-statistics well over 10 (individually and overall). Second, 
confounders of genetic variants on exposure may exist, typically as a result of population 
stratification; therefore, a homogeneous population is generally necessary for MR studies, with 
correction for population stratification, [83, 84] as used here. Third, with regard to the exclusion-
restriction assumption, review of the SNPs in PhenoScanner suggested some horizontal 
pleiotropy. However, estimates remained nonsignificant after removing outliers statistically (in 
the MR-PRESSO analysis). The low MR-Egger I2 value of 5.42% suggests low heterogeneity 
across the SNPs included in the MR-Egger analysis. Fourth, effect sizes, even if nonsignificant, 
may not correspond to clinical significance, nor indicate effects of a clinical intervention at a 
future time, either due to the importance of cumulative exposure or time-dependent exposure. 
Even with a nonsignificant effect size, these two IMIDs do co-occur, if infrequently, and this can 
be clinically significant. [64] Fifth, CD and RA are more common in women than men, but sex-
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specific analysis is not publicly available. Sixth, MR studies usually require extremely large 
sample sizes. The GWAS used in this study were both modestly large (17,897 cases and 33,977 
controls for CD, 19234 cases and 61565 controls for RA); in order for the effect size to reach 
statistical significance, a sample size of nearly 300,000 (over 3.5 times what was available) 
would have been necessary; this would represent about 20% of people with RA in the U.S. [93] 
(Calculation provided in Appendix 2). Finally, an important current limitation of all 
observational studies is that they can only address causal factors of disease incidence, but not 
issues related to disease progression; studies of disease progression (and any studies of patients) 
are open to selection bias because they are missing those who have already died because of the 
exposure or because of competing risk of the outcome, [83, 84] of if participation in the exposure 
GWAS takes place before development of the outcome can occur. 
CONCLUSION 
This Mendelian randomization study suggests that there is not a direct causal link between 
Crohn’s Disease and rheumatoid arthritis. Other causal pathways were proffered, including 
shared causal partners including TNF-alpha and IL-6 overexpression. It is also possible that no 
causal association was seen due to selection bias, due to the expected age distribution of the 
exposure GWAS. 
KEY MESSAGES 
• Mendelian randomization is a powerful method that can determine causal relationships 
between exposures and outcomes, if appropriate instruments can be identified. 
• Although some IMIDs co-occur, CD does not cause RA; co-occurrence of CD and RA 
may be due to common causes. 
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• It is also possible that selection bias related to the expected age distribution of the 
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Table 3.1. 121 SNPs identified in MR-base as associated with CD (p<5x10-8), and their 
location as determined in PhenoScanner. Red text indicates possible pleiotropy (SNPs also 
associated with RA); yellow highlighting indicates 21 SNPs eliminated in MR-PRESSO 


















































































































































Table 3.2. Mendelian randomization association of CD on RA, based on 113 independent 
SNPs* (p-values all <5x10-8).  







MR Egger 0.92 0.67-1.18 0.54 2048.35 (0) 0.65 5.42% 
Weighted median 0.98 0.94-1.03 0.49 
   
Inverse variance weighted 0.97 0.88-1.07 0.59 2052.11 (0) 
  
MR-PRESSO 1.00 0.64-1.36 0.90    
 




















Chapter 4: A Phenome-Wide Association Study to Assess Potential New Targets for 




A recent use of Mendelian randomization (MR) studies and Phenome-Wide Association Studies 
(PheWAS) involves using genetic variants that predict response to treatment to identify both on-
target and off-target mechanistic effects of a pharmacologic intervention. The goal of drug 
repurposing is to identify new therapeutic areas as potential new targets for existing treatments. 
Interleukin-6 is a cytokine that is implicated as a cause of rheumatoid arthritis (RA), and 
tocilizumab (TCZ) is a therapy targeting IL-6 inhibition that is approved for treatment of RA. 
The goal of the current study is to use MR to explore the scope for repurposing TCZ to 
characterize possible additional uses of and off-target effects of this treatment. 
Methods 
One single nucleotide polymorphism (SNP) predicting response to TCZ in RA patients was 
identified, rs7529229. The PheWAS (Phenome-wide Association Study) function in the MR-
base web-based application was used to identify traits associated with this SNP to use as 
potential drug targets for inclusion in the analysis. As this is an agnostic search, a p-value 
threshold of 2.4x10-6 was used based on a Bonferroni correction. The PheWAS provided effect 





The SNP rs7529229 predicting response to TCZ in RA was associated with 21,031 traits. 
Seventeen of these met the Bonferroni corrected p-value threshold for statistical significance. Of 
these, three were excluded from consideration: abdominal aortic aneurysm, due to missing 
associations, and two traits described as “Blood clot  DVT  bronchitis  emphysema  asthma  
rhinitis  eczema  allergy diagnosed by doctor: None of the above,” as these did not indicate a 
trait. Among the other 10 unique traits, four showed an inverse association with the SNP 
predicting response to TCZ: RA, coronary heart disease (CHD), and two blood counts (red cell 
distribution width and granulocyte percentage of myeloid white cells). Six traits were positively 
associated with this SNP, meaning use of TCZ may increase the risk of the following: eczema, 
asthma, a less specific trait of hay fever, allergic rhinitis or eczema, tonsillectomy, and two 
additional blood counts (mean corpuscular hemoglobin and monocyte percentage of white cells). 
Conclusions 
As rs7529229 predicts response to TCZ in RA patients, it was expected that there would be an 
inverse association between the SNP and RA. Other studies have already evaluated the inverse 
association between this SNP and CHD, suggesting CHD as a potential target for TCZ. The 
positive associations with asthma was somewhat unexpected, as some studies have suggested a 
potential for IL-6 inhibition in asthma. The positive associations with eczema were expected as 
this was reported in the clinical trial program for TCZ and in other PheWAS of SNPs associated 
with IL-6 levels. The impact of TCZ on various blood counts are difficult to interpret.  The 
direction of the association with asthma is surprising, even though a recent PheWAS reported a 
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Mendelian Randomization (MR) is an important tool that facilitates causal inference from 
observational studies. This study design can allow for avoidance of a common problem in 
epidemiologic studies, confounding,  [11] because it takes advantage of the random allocation of 
genetic make-up at conception. MR compares disease status by genetically predicted exposure to 
obtain unconfounded estimates. MR implementation has been facilitated by the increasing 
availability of GWAS genotyping millions of single nucleotide polymorphisms (SNPs). A recent 
extension of MR is to use genetic variants that predict response to treatment both as validation of 
efficacy of the treatment in the target population and to identify appropriate patient groups as 
new potential targets for specific existing treatments. [12] Drug target validation and repurposing 
studies can use these genetic variants as proxies to identify both on-target and off-target 
mechanistic effects of a pharmacologic intervention. As an example, a GWAS has identified a 
SNP, rs7529229, that predicts response to tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, 
in rheumatoid arthritis (RA) patients. [13] Drug repurposing seeks to identify new therapeutic 
areas as potential new targets for existing treatments.  
The goal of the current study is to use MR to explore the scope for re-purposing TCZ, an existing 
and approved treatment for RA, as well as to characterize possible off-target effects of this 
treatment.  
Interleukin-6 in RA 
IL-6 is a cytokine that induces protein synthesis in hepatocytes, and increased serum IL-6 has 
been seen in acute conditions including surgery, burns, and infections, as well as in chronic 
conditions, such as RA. In RA patients, the IL-6 -174G/C variant has been associated with RA in 
both European and Asian populations. [41] IL-6 promotes joint inflammation through vascular 
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endothelial growth factor (VEGF), levels of which are associated with RA disease activity. IL-6 
is found in synovial fluid and serum of RA patients, with levels corresponding to disease activity 
and joint damage. [89] 
Tocilizumab 
Tocilizumab (TCZ) is an IL-6 receptor antagonist marketed by Genentech under the brand name 
Actemra. [106] It is approved for the following indications: moderate to severe RA in adults with 
inadequate response to disease-modifying antirheumatic drugs (DMARDs); giant cell arteritis in 
adults; active polyarticular juvenile idiopathic arthritis (JIA) in children age 2 and older; active 
systematic JIA in children age 2 and older; chimeric antigen receptor T-cell induced severe or 
life-threatening cytokine release syndrome in adults and children age 2 and older. TCZ binds to 
IL-6 receptors sIL-6R and mIL-6R (soluble and membrane-bound) to inhibit signaling through 
these receptors. IL-6 is a pro-inflammatory cytokine which is produced by T-cells, B-cells, 
lymphocytes monocytes and fibroblasts. It is also produced by synovial and endothelial cells, 
which causes local IL-6 production in joints affected by RA. [106]  
Drug target validation and identifying new targets 
Genetic validation of potential drug treatments is increasingly used to facilitate drug 
development and anticipate side-effects. Mutations in the PCSK9 gene have been found to 
predict familial hypercholesterolemia and coronary artery disease; leading to two drugs that 
target this gene: evolocumab (Repatha, marketed by Amgen) and alirocumab (Praluent, marketed 
by Regeneron). [29] Lovostatin, the first of the statins and approved for primary and secondary 
prevention of coronary artery disease, inhibits HMG-CoA reductase. Many other genetic 
differences that identify susceptibility to disease have been discovered using GWAS, creating 
many potential drug targets. [30] Schmidt and colleagues describe four genes (HMGCR, PCSK9, 
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NPC1L1, and CETP) with effects on lipids and/or coronary heart disease where genetic 
validation using Mendelian randomization has confirmed the findings of clinical trials. The 
authors also provide guidance on the “selection of genes encoding druggable proteins” for use in 
drug target validation MR studies. [32] Nelson and colleagues used the Informa Pharmaprojects 
database to identify 22,270 drugs with 1,824 genetic targets, creating 19,085 drug-target pairs 
covering 705 indications, including 651drug-target pairs for RA. [33] Tumor necrosis factor 
alpha (TNF-a) is implicated in both CD and RA; adalimumab (Humira, marketed by AbbVie) 
targets TNF-a. [31] Interleukin 6 is implicated as a cause of RA, and tocilizumab (Actemra, 
marketed by Genentech) is a therapy targeting IL-6 inhibition. [13, 106] 
MR studies have become a method for identifying new target indications for approved drugs. An 
MR study confirmed that three SNPs associated with interleukin-18 (IL18) were associated with 
an increase in susceptibility for Crohn’s disease (OR 1.15, 95% CI = 1.01–1.31, p-value = 
0.041); the authors note that an anti-IL18 monoclonal antibody recently failed efficacy goals in a 
phase II trials for type 2 diabetes mellitus, but these MR results suggest another indication target. 
[124]  Zheng and colleagues provide a summary of recent genetic target drug validation and 
repurposing MR studies with varying exposures and the outcome of CHD in most cases [13, 125-
135]. However, MR has not been used extensively to investigate drug validation and repurposing 
for RA treatments.  
Using MR to identify new target indications can be cost-effective and time-saving. The cost of 
developing new molecular entities (NMEs) is in the billions of dollars, and the process can take, 
on average, over 12 years. [29, 30] Less than 10% of drugs are eventually approved by the FDA 
or another health authority. [29]  Drug targets with genetic associations with disease have a much 
higher likelihood of succeeding and receiving regulatory approval. [29, 33, 40] When causal 
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genetic variants can be identified through GWAS, this genetic evidence has been shown to 
increase drug approval by more than two-fold. [29] Using genetic evidence could decrease cost 
of drug development, due to fewer failed clinical trials. One estimate suggests that if the 
proportion of drugs in development with genetic targets were increased from 15% (the current 
proportion) to 50%, research and development costs would decrease by anywhere from 9% to 
35%. [29]  
PheWas 
PheWAS is a method to assess genotype-phenotype associations consistently and 
comprehensively. The method looks for associations of specific SNPs with many potential 
clinical outcomes or phenotypes. It is a complement to the GWAS method. Whereas GWAS 
typically use a set of SNPs to identify associations of all genotypes with a single or small number 
of phenotypes, PheWAS examines the associations of specific genotypes with all phenotypes. 
PheWAS can be conducted by analyzing genetic data from large, population-based cohort 
studies. The National Human Genome Research Institute (NHGRI) has created a repository for 
US-based cohorts called the Population Architecture using Genomics and Epidemiology (PAGE) 
network. [136] Other GWAS are available in the MR-base web-based platform. [57] The GWAS 
Catalog available on the MR-base platform is provided jointly by the National Human Genome 
Research Institute (NHGRI) and the European Bioinformatics Institute (EMBL-EBI), and can be 
found at https://www.ebi.ac.uk/gwas/. [137]   
PheWAS can also be conducted using of electronic medical records (EMRs). The first large-
scale PheWAS using EMRs looked through 3,144 SNPs and 1,358 phenotypes from EMRs of 
people of European descent, and the method confirmed 66% of previously identified associations 
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and suggested 63 new associations of outcomes including autoimmune, hematologic, neoplastic, 
circulatory, endocrine, and other diseases at a significance level of p<5.6x10-6. [138] [34-36] 
Studies have identified SNPs associated with soluble fraction of the IL6 receptor (sIL6R) and 
reviewed associated traits. PheWAS have evaluated traits associated with rs4129267, which is an 
sIL6R variant, and found positive, statistically significant associations with monocyte count, 
mean platelet volume, eczema, and asthma. Mendelian randomization using 34 SNPs associated 
with sIL6R circulating levels showed causal inverse associations with various types of stroke, 
atrial fibrillation, coronary artery disease, abdominal aortic aneurism, and RA, suggesting 
protective effects of IL-6 inhibition, and positive associations with eczema and asthma, 
suggesting IL-6 inhibition increases risk of these diseases. Also included in these analyses were 
heritable longevity; sIL6R was associated with parental age at death, and various blood 
parameters, of which only C-reactive protein was significantly, inversely associated with sIL6R 
levels. [51] Another PheWAS reviewed other IL6R SNPs (rs2228145; rs4129267), in patients in 
the Million Veteran Program (MVP) with results replicated in data from the UK Biobank and 
Vanderbilt University Biobank. Significant inverse associations between these SNPs and the 
following traits were found: aortic aneurysm, ischemic heart disease (including coronary 
atherosclerosis, ischemic heart disease, and myocardial infarction), and vascular diseases such as 
peripheral vascular disease and atherosclerosis of the extremities. Significant positive 
associations were identified for skin conditions such as atopic dermatitis (eczema), seborrheic 
dermatitis, and erythematosquamous dermatosis. Several pulmonary, renal, and eye conditions 
were also positively associated with these IL6R SNPs, as were two musculoskeletal conditions 
(acquired deformities of finger and gouty arthropathy). [52] While these two PheWAS identified 
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traits associated with SNPs that are IL-6 inhibitors, a search of the literature did not find any 
PheWAS that specifically evaluated traits associated with the specific SNP rs7529229.  
METHODS 
Data sources 
rs7529229 as a predictor of response to TCZ  
Forty studies from the US, UK, and Europe with 133,499 participants contributed to a biomarker 
study that evaluated IL-6, C-reactive protein (CRP), total cholesterol, HDL-cholesterol, LDL 
cholesterol, and fibrinogen. Seventeen of these 40 studies, with 29,978 participants, contributed 
IL-6 data. These data enabled identification of SNP rs7529229 as associated with increased log 
circulating IL-6 concentration, consistent with IL-6 inhibition from TCZ infusions for RA every 
four weeks (posology 4-8mg/kg). For each minor allele, the mean log IL-6 concentration 
increase was 9.45% (95% CI 8.34–10.57; p=8·41×10–⁶⁸). Mean ages of participants in the 
contributing studies ranged from 46 years to 75 years, with one outlier (mean age 26) and one 
study which did not report age. [13] 
Genetic predictors of traits associated with rs7529229 
A wide range of traits from the PheWAS were obtained from GWAS that are available in the 
MR-base web-based platform. [57] [137]  Nearly all of the data for these traits came from the 
UK Biobank. The UK Biobank enrolled participants in the UK from 2006-2010. All participants 
were intended to be aged 40 to 69 years at enrollment. Participant data were captured in different 
ways; some by self-report, others by physical assessment. Genetic data are available for 
approximately 488,000 UK Biobank participants.  
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The CARDIoGRAMplusC4D GWAS provided data for CHD, one of the traits included in the 
PheWAS; this GWAS is a meta-analysis of multiple GWAS including participants of European 
and South Asian descent, with 15,420 CHD cases and 15,065 controls; [139]   
RA data came from two sources. One was a meta-analysis of 11,475 cases, of whom 7,222 were 
ACPA positive, 3,297 were ACPA negative, and 957 were unassigned), and 15,870 controls in 
participants of European descent. [140] The other RA data source combined 22 GWAS of which 
18 studies included participants of European background and 4 studies included those of Asian 
background. Among participants, 88.1% were seropositive for anti-citrullinated peptide antibody 
(ACPA), 9.3% were seronegative, and 2.6% had unknown antibody status. The sample includes 
19234 cases and 61565 controls. [65-67] 
Statistical analysis 
The SNP of interest was searched using the PheWAS function in MR-base [57] to identify other 
potential drug targets for TCZ, based on traits noted as associated with this SNP. The Bonferroni 
correction was used to account for multiple comparisons. The traits were aligned so that the 
minor allele was C for all traits to ensure appropriate direction of association with the SNP 
among traits. 
PhenoScanner [80] was searched to identify the effect allele and its effect allele frequency 
(EAF).  
Protection of human subjects 
Deidentified, publicly available summary data were used in this study. Institutional Review 




The single SNP rs7529229 identified as a predictor of response to TCZ in RA [13] was reviewed 
in the MR-base PheWAS function [57] to determine other traits associated with the SNPs. This 
PheWAS identified 21,031 traits associated with this SNP. The Bonferroni correction yielded a 
p-value threshold of 2.4x10-6, which 17 of the 21,031 traits met. 
PhenoScanner [80] showed that the effect allele is C and has an effect allele frequency (EAF) of 
0.3738 in people of European descent. The 17 traits that were statistically significant following 
the Bonferroni correction were aligned on the minor allele (C) to allow for comparisons and to 
understand the direction of associations with rs7529229. 
Among these 17 traits, three were excluded from further review as follows: abdominal aortic 
aneurism, due to missing estimate, which made the association uninterpretable, and two traits 
described as “Blood clot  DVT  bronchitis  emphysema  asthma  rhinitis  eczema  allergy 
diagnosed by doctor: None of the above,” as these did not indicate a trait.  
Several of these traits appear in the PheWAS more than once due to the availability of multiple 
data sources in the GWAS catalog for some traits. [137]  Therefore, these 14 listed traits actually 
represent 10 unique traits. 
Four traits showed an inverse association with the SNP predicting response to TCZ, suggesting 
use of TCZ may lower risk of the trait: RA (p-values 1.1430x10-07 and 1.8000x10-08, from two 
different data sets); coronary heart disease (CHD; p-value 2.5x10-07), and two blood counts (red 
cell distribution width, p-value 4.1350x10-07 and granulocyte percentage of myeloid white cells, 
p-value 1.8330x10-06).  
Six traits were positively associated with this SNP, suggesting use of TCZ may increase the risk 
of the following: asthma (p-values both 1.6x10-6 from two different data sets), eczema (p-values 
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6.6x10-8 and 3.4x10-8, from two different data sets), a less specific trait described as hay 
fever/allergic rhinitis/eczema (p-values 2.2x10-14 and 3.4x10-13, from two different data sets), 
tonsillectomy (p-value 1.10x10-06), and two additional blood counts (mean corpuscular 
hemoglobin, p-value 3.95x10-07 and monocyte percentage of white cells, p-value 6.93x20-09).  
This PheWAS can be found in Table 4.1. 
DISCUSSION 
These results are essentially unsurprising. An inverse association between rs7529229 and RA is 
to be expected, as RA is an approved indication for TCZ. [106] The inverse association between 
rs7529229 and CHD in particular has also been described, [13] as has this relation between other 
IL-6 inhibiting SNPs and CHD. [51, 52] The effects on blood counts, whether positive or 
negative, are difficult to interpret, and have been reported; [51, 52] additionally, changes to 
blood counts are described as potential adverse events in the TCZ product information. [106] 
Eczema has also been reported in the clinical trial program, [141] which reinforces the positive 
association between rs7529229 and eczema; this too has been reported in other IL-6 inhibitor 
PheWAS. [51, 52] 
The positive association between rs7529229 and asthma is more interesting and possibly 
unexpected. A negative association would be more expected, because IL-6 has a plausible role in 
the pathogenesis of asthma. Lung epithelial cells produce IL-6 in response to respiratory viruses, 
allergens, or exercise. [142, 143] Circulating IL-6 is elevated in patients with asthma, [144] 
including in the bronchoalveolar lavage fluid (BALF) of asthmatic patients; [143, 145] this 
suggests that the role of IL-6 is more than just pro-inflammatory as this elevated level is seen in 
both allergic and intrinsic asthma. IL-6 is associated with both viral infections, which can lead to 
exacerbations of asthma, and obesity, which is associated with severity of asthma. [143, 146] IL-
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6 levels have been found to be associated with lung function; forced expiratory volume in 1 
second (FEV1) was shown to be inversely associated with IL-6 levels in patients in several 
studies, and in obese asthmatic patients, a correlation was seen between serum IL-6 levels and 
impaired lung function. These results suggest that IL-6 may be involved in the pathogenesis of 
asthma, and suggest that IL-6 may be a target for asthma treatment. [142, 143] However, this 
PheWAS suggests that an IL-6 inhibitor would not provide benefit for asthma patients and may 
actually cause increased risk of asthma. This is reinforced by a similar finding in the PheWAS 
for another IL-6 inhibiting SNP, rs4129267. [51] Therefore, it is possible that the IL-6 processes 
in asthma are not actually pathogenic, but instead are involved in the disease process in other 
pro-inflammatory ways. 
Strengths and limitations 
There are strengths and limitations to the PheWAS method. A strength of PheWAS is the 
availability of large GWAS data sets; the size of these studies enables identification of many 
traits associated with specific SNPs. PheWAS allow evaluation of some diseases that may not be 
considered to have genetic effects, such as specific blood counts. A major benefit of PheWAS is 
that it provides a method for searching for other drug targets, which can save substantial time 
and money. However, any PheWAS, but particularly in the context of drug target repurposing, is 
hypothesis-generating only; other studies such as randomized controlled trials are still required to 
confirm the effect suggested in a PheWAS.  A Bonferroni correction for statistical significance 
may not be appropriate if the traits are not independent from each other. Differences across 
populations could affect both the expected allele frequency for the minor allele (which can vary 
by population) and also access of different populations to medical care from which diagnosis and 
ultimately identification of traits in a PheWAS are possible. [85] 
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Given the ongoing identification of new SNPs that are associated with IL-6 levels, and given the 
importance of IL-6 in the pathology of so many diseases, it will be important to continue to 
consider whether any of these SNPs besides rs7529229 are specifically associated with response 
to an IL-6 inhibitor such as TCZ. Other SNPs associated with TCZ response have been identified 
in a small number of patients, but to date these have not been validated. [147]  
CONCUSION 
TCZ is already known to be inversely associated with RA and CHD and positively associated 
with eczema and asthma. This study did not identify new targets for TCZ. As more SNPs are 
identified as associated with IL-6 levels, it may be possible to determine additional SNPs 
associated with TCZ or other IL-6 inhibitors, from which point new drug targets may be 
identified. 
KEY MESSAGES 
• Phenome-wide association studies can be used to identify potential new drug targets. 
• The current PheWAS did not identify any new targets for TCZ, an IL-6 inhibitor. 
• More SNPs associated with IL-6 levels, and IL-6 inhibiting drug therapies, may enable 
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Table 4.1. PheWAS for rs7529229, including 10 unique traits (listed as 14 traits due to multiple data sources). Negative beta 
indicates inverse association between rs7529229 and trait (decreased risk); positive beta indicates positive association between 
rs7529229 and trait (increased risk).  
 
ID Trait Consortium Sample 
Size 
Beta EA   OA Beta Pval SE Cases Controls 
283 Rheumatoid 
arthritis 
  27345 -0.1009259 C  T -0.1009259 1.1430E-07   11475 15870 
833 Rheumatoid 
arthritis 
  80799 0.07696104 C  T -0.076961 1.8000E-08 0.01417598 19234 61565 
7 Coronary heart 
disease 
CARDIoGRAMplusC4D 184305 0.048757 C  T -0.048757 2.5000E-07 0.0094539 60801 123504 






























illness code  self-
reported: 
eczema/dermatitis 
Neale Lab 337159 0.00216192 C  T 0.00216192 3.3846E-08 0.00039162 8718 328441 
UKB-
b:20296 

























allergic rhinitis or 
eczema 
MRC-IEU 462013 -0.0067188 C  T 0.00671876 2.2000E-14 0.00087962 106201 355812 
UKB-
a:447 
Blood clot  DVT  
bronchitis  
emphysema  
asthma  rhinitis  
eczema  allergy 
diagnosed by 
doctor: Hayfever  
allergic rhinitis or 
eczema 
Neale Lab 336782 0.00756788 C  T 0.00756788 3.3372E-13 0.0010395 77891 258891 












170494 0.02081604 C  T 0.02081604 6.9300E-09 0.00359355 NA NA 
 
EA: Effect allele; OA: other allele 
 
 111 
CHAPTER 5: DISCUSSION 
SUMMARY AND DISCUSSION 
These Mendelian randomization studies have shown a decreased risk of CD in RA patients and 
no effect of CD on RA, and the PheWAS for rs7529229 did not suggest new targets for 
tocilizumab, an IL-6 inhibitor currently approved for RA and several other indications. 
Co-occurrence of RA and CD vs co-occurrence of IMIDs 
While IMIDs have been shown to co-occur in 9-10% of patients, [8] RA and CD specifically co-
occur far less frequently, with estimates ranging from 0.0027%-1.7%. [12][13] It seems that 
other IMIDs may co-occur, but not specifically RA with CD. This is one factor that could have 
contributed to the failure to find any causal association between CD and RA, but it does not 
explain the decreased risk of CD in RA patients found in this MR study. 
Shared etiology: the role of interleukin-6 (IL-6)]inhibition in RA, CD 
Pre-treatment of subclinical CD in RA patients 
There are thought to be multiple common contributing causes of RA and CD, including IL-6 and 
TNF-a overexpression. A possible explanation for the decreased risk of CD in RA patients is that 
treating this overexpression of a causal cytokine could simultaneously treat diagnosed RA and 
preemptively treat subclinical CD, which could prevent CD from being clinically diagnosed. As 
some medications are approved for the treatment of both RA and CD (e.g., adalimumab, 
marketed as Humira by Abbvie), [31] a shared causal pathway makes sense. However, this 
explanation would suggest the opposite to be true: that in CD patients, pre-treatment of 
subclinical RA would lead to the decreased risk of RA in CD patients, but this result was not 
seen in the second MR study. 
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IL-6 in RA and CD 
IL-6 is a cytokine that induces protein synthesis in hepatocytes, and increased serum IL-6 has 
been seen in acute conditions including surgery, burns, and infections, as well as in chronic 
conditions, such as CD and RA. Serum IL-6 concentrations were found to be higher in CD 
patients than in healthy controls, and a nonsignificant trend was found toward higher serum IL-6 
in CD patients with active disease versus inactive disease. [102]  In RA patients, the IL-6 -
174G/C variant has been associated with RA in both European and Asian populations. [41] IL-6 
promotes joint inflammation through vascular endothelial growth factor (VEGF), levels of which 
are associated with RA disease activity. IL-6 is found in synovial fluid and serum of RA patients, 
with levels corresponding to disease activity and joint damage. Serum IL-6 levels were elevated 
in RA patients compared to controls, and higher levels were associated with more severe disease 
activity as measured by the DAS28. [123] 
IL-6 in asthma 
The positive association of rs7529229 with asthma is more interesting and somewhat 
unexpected. A negative association was expected, because IL-6 has a plausible role in the 
pathogenesis of asthma. Lung epithelial cells produce IL-6 in response to respiratory viruses, 
allergens, or exercise. [142, 143] Circulating IL-6 is elevated in patients with asthma, [144] 
including in the bronchoalveolar lavage fluid (BALF) of asthmatic patients; [143, 145] this 
suggests that the role of IL-6 is more than just pro-inflammatory as this elevated level is seen in 
both allergic and intrinsic asthma. IL-6 measured in BALF could aid in identifying patients with 
for treatment with an IL-6 inhibitor. IL-6 is associated with both viral infections, which can lead 
to exacerbations of asthma, and obesity, which is associated with severity of asthma. [143, 146] 
IL-6 levels have been found to be associated with lung function; forced expiratory volume in 1 
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second (FEV1) was shown to be inversely associated with IL-6 levels in patients in several 
studies, and in obese asthmatic patients, a correlation was seen between serum IL-6 levels and 
impaired lung function. These results suggest that IL-6 may be involved in the pathogenesis of 
asthma, and that IL-6 may be a target for asthma treatment. [142, 143] However, this PheWAS 
suggests that an IL-6 inhibitor would not provide benefit for asthma patients and may actually 
cause increased risk of asthma. This is reinforced by a similar finding in the PheWAS for another 
IL-6 inhibiting SNP, rs4129267. [51] Therefore, it is possible that the IL-6 processes in asthma 
are not actually pathogenic, but instead are involved in the disease process in other, pro-
inflammatory ways. 
RA as protective for CD 
It is possible that RA is in fact protective for CD. A mechanism for this has not been described. 
Further research would be necessary to understand a protective mechanistic effect of RA on CD. 
Problems with data sources for RA and CD 
A feasible reason for the results showing a reduced risk of CD in RA patients and no causal 
relationship between CD and RA is bias related to the age distribution of the RA and CD GWAS 
used in these MR studies.  
The first MR study evaluated the causal effect of RA on CD. Since RA is often diagnosed at an 
older age than CD, [17, 18, 24] if patients enrolled in the GWAS with diagnosed RA but without 
having been diagnosed with CD, then those participants may have been unlikely ever to develop 
CD. This makes it seem like RA is protective for CD.  This is not a mechanistic protective effect 
of RA, but a function of people diagnosed with RA but not CD enrolled in the GWAS. This bias 
is likely a strong factor in these results.  
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The second MR study evaluated the causal effect of CD on RA. CD is has two peak age ranges 
for diagnosis, and the first is several decades younger than the second, which essentially overlaps 
with age of diagnosis of RA. [17, 18, 24] The average age of all participants in the full CD 
GWAS was not found, but one of the component GWAS reported that 60% of participants were 
under age 50. [67] Therefore, is possible that patients were enrolled in the CD GWAS prior to an 
age of RA diagnosis.  This would suggest that RA could not be detected in the analysis because 
there were too few GWAS participants with an RA diagnosis simple due to their age. A different 
study with an age distribution skewed older may have yielded a different result.  
A further problem with the GWAS for RA and CD is the lack of clarity regarding the control 
groups. It is not clear whether each study had “healthy controls”—those lacking RA in the CD 
GWAS or those lacking CD in the RA GWAS. A control group in a case-control study should 
represent the underlying cohort from which the cases were drawn, suggesting that there should 
have been RA patients in the controls for CD and vice versa. This could not be ascertained from 
descriptions of the RA and CD studies. Use of healthy controls would likely impair an ability to 
detect a true association between the two diseases, including direction of such an association. 
Strengths and limitations 
There are many strengths to the MR method. The F-statistics suggested strong instruments, and 
large sample sizes were available for both the MR studies and the PheWAS. Sample size allows 
identification of many traits in PheWAS; this method is also useful because it allows evaluation 
of traits not always considered genetic. This PheWAS was consistent with two other PheWAS of 
other SNPs implicated in IL-6.  
There are also limitations to the MR method. First, the method relies on strong assumptions 
which can be difficult to verify empirically. This method requires genetic instruments that 
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predict the outcome. GWAS have provided such instruments for RA, CD, and response to TCZ 
in RA patients. However, genetic variants may have only a small effect on these diseases, which 
could introduce bias due to weak instruments. [83, 84]  
Second, confounders of genetic variants on exposure may exist, typically as a result of 
population stratification; therefore, a homogeneous population is generally necessary for MR 
studies, with correction for population stratification; the current studies use fairly homogeneous 
populations, although the RA GWAS, which includes participants of both European and Asian 
descent, may be less so than the others [83, 84].  
Small effect sizes may not correspond to clinical significance, nor indicate effects of a clinical 
intervention at a future time, either due to the importance of cumulative exposure or time-
dependent exposure. [64]  Additionally, low co-occurrence of RA and CD does not indicate lack 
of importance in those patients. 
MR studies are only as good as the data sources available. The RA and CD data sources lacked 
clarity on several important issues, including age range and composition of control groups. This 
information would have enabled better interpretation of these MR results.  
Finally, an important current limitation of MR studies is that they only address causal factors of 
disease incidence, but not issues related to disease progression; studies of disease progression 
and studies of patients are open to selection bias because they are missing those who have 
already died because of the exposure or because of competing risk of the outcome. [83, 84] 
There are also strengths and weaknesses to PheWAS. A strength of PheWAS is the availability 
of large GWAS data sets; the size of these data sets enables identification of many traits 
associated with specific SNPs. PheWAS allow evaluation of some diseases that may not be 
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considered to have genetic effects, such as specific blood counts. A major benefit of PheWAS is 
that it provides a method for searching for other drug targets, which can save substantial time 
and money. However, PheWAS are hypothesis-generating only; other studies such as 
randomized controlled trials are still required to confirm the effect seen in a PheWAS.  A 
Bonferroni correction for statistical significance may not be appropriate if the traits are not 
independent from each other. Differences across populations could affect both the expected 
allele frequency for the minor allele (which can vary by population) and also access of different 
populations to medical care from which diagnosis and ultimately identification of traits in a 
PheWAS are possible. [85] 
CONCLUSIONS AND SUGGESTIONS FOR FURTHER RESEARCH 
These Mendelian randomization studies determined that rheumatoid arthritis is associated with a 
decreased risk of Crohn’s disease and that Crohn’s disease has no causal effect on rheumatoid 
arthritis. It is likely that these results were driven by bias due to the age distributions of the 
GWAS populations, though a protective effect of RA on development of CD cannot be excluded. 
In the first MR study, GWAS participants who have made it to the age of developing RA without 
ever having developed CD are individuals who are unlikely to have ever developed CD. In the 
second MR study, GWAS participants with CD may have been too young to have developed RA, 
meaning it was not possible to determine an association between the two disease. Control groups 
selected for each GWAS may have also affected these results, and the lack of clarity on these 
control groups to some extent impairs interpretation of the results. 
The results of the PheWAS are essentially unsurprising. An inverse association between 
rs7529229 and RA is to be expected, as RA is an approved indication for TCZ. [106] The inverse 
association between rs7529229 and CHD in particular has also been described, [13] as has this 
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relation between other IL-6 inhibiting SNPs and CHD. [51, 52] The effects on blood counts, 
whether positive or negative, are difficult to interpret, and have been reported; [51, 52] 
additional, changes to blood counts are described as potential adverse events in the TCZ product 
information. [106] Eczema has also been reported in the clinical trial program, [141] which 
reinforces the positive association between rs7529229 and eczema, which has been reported in 
other IL-6 inhibitor PheWAS. [51, 52] The positive association between rs7529229 and asthma 
is more interesting and possibly unexpected. A negative association would be more expected, 
because IL-6 has a plausible role in the pathogenesis of asthma; however, this PheWAS suggests 
that an IL-6 inhibitor would not provide benefit for asthma patients and may actually cause 
increased risk of asthma. This is reinforced by a similar finding in the PheWAS for another IL-6 
inhibiting SNP, rs4129267. [51] Therefore, it is likely that the IL-6 processes in asthma are not 
actually pathogenic but are involved in the disease process in other ways. 
KEY MESSAGES 
• Mendelian randomization can determine causal associations between exposures and 
outcomes, if appropriate instruments are identified and adequate sample sizes are 
available.  
• These MR studies showed a lower risk for CD in RA patients and no causal effect of CD 
on RA, which may be due to bias in the underlying studies.  
• However, a protective effect of RA on CD cannot be ruled out; further research is 
required to determine a biological mechanism for this effect. 
• PheWAS can be used to identify potential new drug targets, but the current PheWAS did 
not identify any new targets for TCZ, an IL-6 inhibitor. 
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• More SNPs associated with IL-6 levels, and IL-6 inhibiting drug therapies, may enable 
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Appendix 1. Power calculation for Specific Aim 1, Chapter 2 
Code for the calculation was provided by Burgess [1] with #notes added. 
#rsq from MR-base output 
#b1 from IVW analysis beta  
#17897 CD cases and 33977 controls 
#total sample 51874 
#ratio 0.52673868 
expit <- function(x) { return(exp(x)/(1+exp(x))) } 
rsq = 0.0578485 # squared correlation 
b1 = 0.1206 # causal effect  
sig = 0.05 # significance level (alpha) 
ratio = 0.526738676 # ratio of cases:controls = 1:ratio 
#minimum effect size to detect given sample size with 80% power is 0.108 
 
#power calculation 
cat("Power of analysis with ", 51874, "participants: ", 















Appendix 2: Power and sample size calculations for Specific Aim 2, Chapter 3 
Code for these calculation was provided by Burgess [1] with #notes added as follows: 
#power calculation  
# beta for IVW 0.02637 
# r2 exposure from MR- base report 0.2097407 
#outcome case and control counts for total n and for ratio 
#RA cases 19234 RA controls 61565 ratio 0.31241777 total 80799 
#determined minimum effect size to provide 80% power 
#beta to produce 80% power=0.05 
 
expit <- function(x) { return(exp(x)/(1+exp(x))) } 
rsq = 0.81582 # squared correlation 
b1 = 0.0505 # causal effect estimate to reach 80% power 
sig = 0.05 # significance level (alpha) 
pow = 0.8 # power level (1-beta) 
ratio = 0.31241777 # ratio of cases:controls = 1:ratio 
#power calc SA2 
 
cat("Power of analysis with ", 80799, "participants: ", 
    pnorm(sqrt(80799*rsq*(ratio/(1+ratio))*(1/(1+ratio)))*b1-qnorm(1-sig/2))) 
#sample size calculation for effect size to reach significance 
cat("Sample size required for ", pow*100, "% power: ", 
    (qnorm(1-sig/2)+qnorm(pow))^2/b1^2/rsq/(ratio/(1+ratio))/(1/(1+ratio))) 
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